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VitageneModulation of endogenous cellular defense mechanisms represents an innovative approach to therapeutic
intervention in diseases causing chronic tissue damage, such as in neurodegeneration. This paper introduces
the emerging role of exogenous molecules in hormetic-based neuroprotection and the mitochondrial redox
signaling concept of hormesis and its applications to the ﬁeld of neuroprotection and longevity. Maintenance
of optimal long-term health conditions is accomplished by a complex network of longevity assurance pro-
cesses that are controlled by vitagenes, a group of genes involved in preserving cellular homeostasis during
stressful conditions. Vitagenes encode for heat shock proteins (Hsp) Hsp32, Hsp70, the thioredoxin and the
sirtuin protein systems. Dietary antioxidants, such as polyphenols and L-carnitine/acetyl-L-carnitine, have re-
cently been demonstrated to be neuroprotective through the activation of hormetic pathways, including vita-
genes. Hormesis provides the central underpinning of neuroprotective responses, providing a framework for
explaining the common quantitative features of their dose response relationships, their mechanistic founda-
tions, their relationship to the concept of biological plasticity as well as providing a key insight for improving
the accuracy of the therapeutic dose of pharmaceutical agents within the highly heterogeneous human pop-
ulation. This paper describes in mechanistic detail how hormetic dose responses are mediated for endoge-
nous cellular defense pathways including sirtuin, Nrfs and related pathways that integrate adaptive stress
responses in the prevention of neurodegenerative diseases. This article is part of a Special Issue entitled: An-
tioxidants and Antioxidant Treatment in Disease.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
In recent years, studies have shown that aging (more correctly de-
ﬁned as longevity) is due to a complex genetic and cellular process
that seems to be partly regulated by sirtuins [1,2] the human and mu-
rine homologs of the Saccharomyces cerevisiae Sir2 that control both
replicative and overall lifespan [3,4]. Findings have also shown that
this gene family regulates longevity in Caenorhabditis elegans and
Drosophila melanogaster [1,2], suggesting that there is an evolutionaryants and Antioxidant Treatment
y, University of Catania, Viale
67; fax: +39 095 580138.
rights reserved.need in many different complex species to preserve these proteins in
the cells. Sirtuins, which are classiﬁed as class III histone deacetylases,
differ from traditional class I and II histone deacetylases [5,6]. They
differ from conventional HDACs in that their substrates range from
metabolic enzymes to structural proteins and histones [7–9].
The activity, stability and intracellular location of nearly all pro-
teins depend on post-translational modiﬁcations (PTMs) that include
phosphor-ylations, acetylations, sumoylations, ubiquitinations, ADP-
ribosylations and nitrations [10]. Most of these highly dynamic pro-
cesses occur as a result of opposing enzyme activity (e.g. kinases
vs. phosphatases, acetylases vs. deacetylases, etc.). Numerous studies
have demonstrated that PTM signaling pathways play a signiﬁcant role
in crosstalk between the cell and its environment and in enabling cells
to become ﬂexible towards change [10]. For this reason, nicotinamide
adeninedinucleotide (NAD) has aroused new interest as it is an
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translational modiﬁcations, such as deacetylationorADP- ribosylation.
The role of NAD in these regulatory processes differs from its involve-
ment in energy metabolism since it is based on the ability to act as an
ADP-ribose donor, thus requiring NAD re-synthesis to avoid depletion
of the intracellularNADpool [11]. The fundamental role ofNAD in energy
metabolism and protein modiﬁcation has an important physiological in-
ﬂuence on the control of cell metabolism, cell death and longevity
[12,13].
Since transient post-translational modiﬁcations such as acetyla-
tion, phosphorylation and ubiquitination determine a rapid and efﬁ-
cient cell response to intra- and extracellular stimuli, they play a
central role in cell signaling cascades. Recent research has identiﬁed
a PTM involving the attachment of a SUMO peptide, a process fre-
quently referred to as SUMOylation that occurs in signaling pathways
both within the nucleus and other parts of the cell. SUMO attachment
is thought to be involved in a number of cell processes, e.g. transcrip-
tion, nuclear transport, DNA repair, mitochondrial activity, plasma
membrane ion channels, cell cycle and chromatin structure. Although
its function is as diverse as its substrates, modiﬁcation of a protein
substrate by SUMO generally alters its interactions with other protein
and DNA molecules [14].
A prediction of oxidative stress theory of aging is that, among spe-
cies, differential rates of aging may be apparent on the basis of intrin-
sic differences in oxidative damage accrual. Although widely
accepted, exceptions to this theory, mostly related to the speciﬁcity
of species, strain and even tissues of investigation, are occurring
more frequently. Proteins are a principal target for oxidative damage
and cysteine residues are highly sensitive to reversible and irrevers-
ible oxidation. To adapt and survive, cells and organisms need to
sense proteotoxic insults and to protect themselves by coordinating
cellular stress response pathways and chaperone networks related
to protein quality control and stability. The mis-assembly or aggrega-
tion of proteins or peptides, in any cell type leads to toxic effects or
proteotoxicity. Despite the abundance and apparent capacity of chap-
erones and other components of homeostasis to re-establish folding
equilibrium, cells do not appear to adapt well to chronic proteotoxic
stress which increases in cancer, metabolic and neurodegenerative
diseases. The use of drugs to modulate cellular stress response path-
ways is emerging as a treatment for human diseases such as neurode-
generative disorders, cardiovascular disease and cancer. For medical
intervention to be successful, the dose must be right, but it can be ex-
tremely difﬁcult to achieve this goal on account of human inter-
individual variation in age, gender, diet, exercise, genetic factors and
health status. The past decade has witnessed considerable progress in
the nature of the dose response in and adjacent to the therapeutic
zones. Long-standing ideas about the nature of the dose–response in a
low dose zone, have been challenged by the hormetic dose–response
which could signiﬁcantly inﬂuence the design of pre-clinical studies,
clinical trials and optimal patient dosing strategies in the treatment of
numerous diseases. The broad cytoprotective properties of the heat
shock response have aroused strong interest in discovering and devel-
oping pharmacological agents that can induce stress responses, includ-
ing carnitines. This paper illustrates themechanisms bywhich hormetic
dose responses are mediated for endogenous cellular defense path-
ways. These include the possible signaling mechanisms through
which, by interplaying metabolism, mitochondrial energetics and acti-
vation of critical vitagenes, the carnitine systemmodulates signal trans-
duction cascades that provide cytoprotection against chronic
degenerative damage associated with aging and neurodegenerative
disorders.
2. The mitochondrial theory of aging
Mitochondria are membrane-enclosed organelles found in eu-
karyotic cells where they generate ATP as a source of chemicalenergy. ATP synthesis occurs through the respiratory or electron
transport chain (ETC) located at the inner mitochondrial membrane,
and consists of ﬁve protein complexes (Complexes I–V) [15–18].
Besides supplying ATP, mitochondria are involved in many other
cell functions including the biosynthesis of heme, cholesterol and
phospholipids [16] and initiation of the apoptotic process [18].
According to the endosymbiosis theory, mitochondria are organelles
that evolved from purpurbacteria approximately 1.5 billion years
ago. Mitochondria have their own genome [17,19] and can replicate
and transcribe their DNA semi-autonomously. Mitochondrial DNA
(mtDNA), like nuclear DNA, is constantly exposed to DNA damaging
agents. For many years it was thought, in mtDNA repair, that exces-
sively damaged mtDNA molecules were simply degraded and
replaced by newly-generated successors copied from undamaged ge-
nomes. However, ﬁndings now indicate that mitochondria possess
the machinery needed to repair genome damage caused by endoge-
nous or exogenous harmful agents. Harman [20,21] suggested that
free radicals are involved in the aging process and that
mitochondria-derived ROS may inﬂuence cellular aging [21]. The
treatment of IMR-90 ﬁbroblasts with N-tertbutyl hydroxylamine (an
antioxidant recycled by the mitochondrial electron-transport chain),
initially gave support to the theory of mitochondrial involvement in
cellular senescence. N-tert-butyl hydroxylamine extends ﬁbroblast
replicative capacity and delays changes in mitochondrial function
due to age by reducing ROS production, preservation of mitochondrial
membrane potential and by increasing the cellular GSH/GSSG ratio
[16]. A more recent study has demonstrated that mitochondria de-
rived ROS play an important and direct role in the shortening of telo-
meres and the onset of senescence [16]. Other ﬁndings have proposed
that mitochondrial dysfunction leads to mitochondrial biogenesis,
thereby increasing the number of cell sites for the production of
ROS that causes telomere shortening [15,18].
On account of its elevated mutagenic propensity, accumulation of
mtDNA during life is thought to be a major cause of age-related dis-
ease. The lack of introns and protective histones, limited nucleotide
excision and recombination DNA repair mechanisms, location in
proximity of the inner mitochondrial membrane with exposure to
an enriched free radical milieu are all factors contributing to a muta-
tion rate that is 10-fold higher in the mtDNA than in the nuclear DNA
(nDNA) [22]. Furthermore, considerable evidence suggests that
mtDNA mutations increase as a function of age, reaching the highest
levels in brain and muscle. It has been reported that more than twen-
ty different types of deletions accumulate in aging human tissues. The
ﬁrst report on an age-related increase in a mtDNA deletion was found
in elderly brain and in Parkinson's disease [22]. This deletion, called
the “common deletion”, was observed between 13-bp sequence re-
peats beginning at nucleotides 8470 and 13447, removing almost a
5-kb region of mtDNA between ATPase 8 and the ND5 genes. The de-
letion takes place during replication of the mtDNA, the missing se-
quence encodes for six essential polypeptides of the respiratory
chain and 5 tRNAs, and has been associated with several clinical dis-
eases, such as chronic progressive external ophthalmoplegia and
Kearns Sayre syndrome. In a comparison with age-matched controls,
an association was found between numerous age-related disorders
and higher levels of mtDNA mutations. In the central nervous system
(CNS), patients with Parkinson's disease were found to have a 17
times higher level of the common deletion in the striatum, compared
to age-matched controls. There is also evidence of higher levels of this
deletion in patients with Alzheimer's disease, parallelling increased
levels in the oxidized nucleotide 8-OH-dG [15]. More than 100 muta-
tions of mtDNA have been associated with human diseas [23]. Pheno-
typic manifestation of mtDNA mutations is extremely broad ranging
from oligosymptomatic patients with isolated deafness, diabetes,
ophthalmoplegia, etc., to complex encephalomyopathic disorders
that may include dementia, seizures, ataxia, stroke-like episode and
so on. There is also a wide range of genotype variants, with
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ing protein coding genes, tRNAs and rRNAs. Although there are some
broad genotype/phenotype correlations, considerable overlap also
occurs. Further research is needed to fully understand the pathoge-
netic mechanisms involved in the expression of mtDNA mutations.
Recent studies have identiﬁed mutations of nuclear genes encoding
subunits of the respiratory chain, particularly those of complex I.
These principally involve infant onset disease with early death. More-
over recent research has shown that the function of the respiratory
chainmay be impaired bymutations affecting othermitochondrial pro-
teins or as a secondary phenomenon to other intracellular biochemical
derangements. An example is Friedreich ataxia where a mutation of a
nuclear encoded protein (frataxin), probably involved in iron homeo-
stasis in mitochondria, results in severe deﬁciency of the respiratory
chain in a pattern indicative of free radical mediated damage
[22,24–26].
Mutations of nuclear encoded proteins involved in cytochrome
oxidase assembly and maintenance have been identiﬁed. As pre-
dicted, they are associated with severe deﬁciency of cytochrome oxi-
dase and Leigh syndrome. Defects of intracellular metabolism,
particularly with excess-free radical generation including nitric
oxide or peroxynitrite, may cause secondary damage to the respirato-
ry chain. This probably plays an important role in Huntington disease,
motor neuron disease (amyotrophic lateral sclerosis) and Wilson dis-
ease. It is important to consider however that mutation and ROS in-
duced DNA damage are different, and the diseases mentioned above
are mostly dependent on genetics and not a causative factor of oxida-
tive stress. Since a commonpathway in the pathogenesis of these disor-
ders appears to be defective oxidative phosphorylation, treatments
designed to improve respiratory chain function may bring amelioration
in the progression of these disorders [23]. Theseﬁndings establish that a
key feature of the aging process is the relationship between age-
associated accumulation of mtDNA mutations and bioenergy dysfunc-
tion, at least in tissues predominantly composed of postmitotic cells,
such as CNS and skeletal muscle.
With regard to mitochondrial bioenergetics, a signiﬁcant decrease
in state 3/state 4 ratio has been seen to occur in brain during aging
[24]. Since this ratio relates to the coupling efﬁciency between elec-
tron ﬂux through the electron transport chain and ATP production,
an increase in state 4 would reduce mitochondrial complexes and
consequently increase free radical species production. A decrease in
state 3/state 4 respiration during aging has been associated with a
signiﬁcant decrease in cardiolipin content in brain mitochondria
[27]. This loss may play a vital role in age-related reduction in mito-
chondrial function, and appears to be associated with both quantita-
tive and qualitative region-speciﬁc protein changes such as decrease
of the inner membrane surface, smaller and fewer cristae, decreased
ﬂuidity and increased fragility. It is known that functional changes
in brain mitochondria are correlated with modiﬁcations in cardiolipin
composition. Acetylcarnitine fed to old rats increased cardiolipin to
levels found in young rats and restored protein synthesis both in
the inner mitochondrial membrane and cellular oxidant/antioxidant
balance, suggesting that cellular bioenergetics in aged rats may bene-
ﬁt from administration of this compound [28]. It is interesting to note
that caloric restriction, a dietary regimen that increases life-span in
rodents, maintains the levels of 18:2 acyl side chains and inhibits car-
diolipin composition changes [29]. It has also been shown to retard
aging associated changes in oxidative damage, mitochondrial oxidant
generation and antioxidant defenses observed during aging [18,30].
Recent ﬁnding indicates that calorie restriction and speciﬁcally re-
duced glucose metabolism induce mitochondrial metabolism to ex-
tend life span in a number of model organisms including
S. cerevisiae, D. melanogaster, C. elegans and possibly mice. In contrast
with Harman's free radical theory of aging, these effects may be
caused by an increase in ROS formation within the mitochondria
leading to an adaptive response that culminates in increased stressresistance thought to ultimately cause a long-term reduction in oxi-
dative stress [31]. This type of retrograde response, termed mitochon-
drial hormesis or mitohormesis, may be involved in the health-
promoting effects of physical exercise in humans and, hypothetically,
impaired insulin/IGF-1-signaling in model organisms. Abrogation of
this mitochondrial ROS signal by antioxidants consistently impairs the
lifespan-extending andhealth-promoting capabilities of glucose restric-
tion and physical exercise, respectively [32]. In short, ROS are essential
signaling molecules needed to promote health and longevity. The con-
cept of mitohormesis therefore provides a common mechanistic de-
nominator for the physiological effects of physical exercise, reduced
calorie uptake and glucose restriction [33].
3. Redox regulation of mitochondrial dynamics fusion and ﬁssion:
role in cell survival
In eukaryotic cells, mitochondria are the principal source of ener-
gy (ATP and NAD+). Neuronal processes such as energy production,
Ca2+ regulation, maintenance of plasmamembrane potential, protein
folding by chaperones, axonal and dendritic transport and the release
and re-uptake of neurotransmitters at synapses all depend on mito-
chondrial function. Mitochondria help neurons to satisfy the high en-
ergy demand required for proper neuronal function since, unlike
other cell types, they cannot switch to glycolysis when oxidative
phosphorylation becomes limited. In response to changing energy de-
mands, cells continually adjust the rate of mitochondrial ﬁssion and
fusion to aid the distribution of mitochondria [18,30]. Mitochondria
also produce large amounts of superoxide anion radical by abstracting
an electron from oxygen in the so-called electron transport chain at
the inner mitochondrial membrane [15]. Mitochondrial respiration
accounts for about 90% of the oxygen consumed in the cell. Most of
this is reduced to water through four consecutive one-electron reduc-
tions in which a small proportion of the oxygen molecules (1–2%) is
converted to superoxide anion radicals. Complexes I and III are recog-
nized the main sites of superoxide production in the respiratory chain
[15] and recent studies have detected up to nine submitochondrial re-
active oxygen species (ROS) generating sites [16]. The resulting su-
peroxide then dismutates either spontaneously or enzymatically
due to superoxide dismutase to form hydrogen peroxide [17] which
may then diffuse through the cell and decompose to form harmful hy-
droxyl radicals, thus damaging the cell through interactions with
macromolecules. These processes cause mitochondria to become a
major source of physiological or endogenous ROS production [18].
Many studies have focused on the harmful effects of ROS, but it is
now clear that mitochondrially generated ROS are also involved in
regulating intracellular signal transduction pathways that result in
cell activities such as proliferation [18]. Mitochondria can produce su-
peroxide in relatively constant amounts, or elicit spontaneous or
environmentally-induced “superoxide ﬂashes” [18] and it is generally
assumed that the main sites of superoxide production in the mito-
chondrial respiratory chain are complexes I and III [18]. Consequently
any impairment in the electron transfer process causes a reduction in
upstream carriers, thus ﬁlling Q cycle electron pool. The cytochrome
(cyt)2 bc1 complex (EC 1.10.2.2) (cyt bc1 complex), situated in the
inner membrane of mitochondria, couples the oxidation of a substrate
quinol (QH2) with the generating proton motive force across the en-
ergy transducing membrane system, where the energy is ultimately
stored in the form of ATP (Fig. 1). Cytochrome bc1 complexes contain
four redox-active metal centers, arranged in two separate chains. The
“high potential chain” consists of the Rieske iron-sulfur (2Fe2S) clus-
ter and cyt c1. The “low potential chain,”which binds to the cyt b sub-
unit of ubiquinol oxidizing complexes, consists of two b-type hemes,
cyt bL and bH labeled for their relatively lower and higher electro-
chemical potentials [34]. Three enzymatic binding sites participate
in catalysis on the cyt bc1 complex, the quinol oxidase (Qo) site, qui-
nol reductase (Qi) site, and a docking site for soluble cyt c on cyt c1.
Fig. 1. The ubiquinone (Q) cycle. The ubiquinone (Q) cycle is initiated when one electron from ubiquinol (QH2) is donated to the Rieske-iron sulfur (R-FeS) protein and the second
electron is donated to cytochrome b. The intermediate moiety is the free radical ubisemiquinone (Qo), which can donate electrons to molecular oxygen to generate superoxide.
Mitochondrial electron transport chain generates superoxide at complexes I, II, and III. Complexes I and II generate superoxide within the mitochondrial matrix. Complex III can
generate superoxide in both the intermembrane space and the matrix. Release of superoxide from complex III into the cytosol is followed by conversion to H2O2 and subsequent
activation of oxidant-dependent (redox) signaling pathway of vitagene network, which results in preconditioning.
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membrane, where protons are released during enzyme turnover.
The Qi site is located toward the negatively charged membrane sur-
face, where protons are taken up during catalysis. The water-soluble
cyt c docking site is located on the c-type cyt representing the termi-
nal electron carrier within the cyt bc1 complex on the positive side of
the membrane. Cyt bc1 complex catalysis is thought to occur by a “Q-
cycle”mechanism. A key reaction in the Q-cycle may be the “bifurcat-
ed” electron transfer at the Qo site, but the exact mechanism has not
yet been clariﬁed [34]. In the bifurcated reaction, QH2 is oxidized at
the Qo site, with one electron being transferred through the high po-
tential chain to reduce cyt c, while the other electron is transferred
through the low potential chain, to reduce a quinoid species (Q or
SQ, depending on the state of the two-electron gate) at the Qi site.
Two turnovers of the Qo site are required to reduce a Qi site Q to a
QH2. Under some conditions, the Q-cycle can be short-circuited by
various “bypass” reactions, some of which yield the superoxide that
is physiologically harmful [18]. The bypass reactions are typically ob-
served in vitro under “partially inhibited” conditions, e.g. in the pres-
ence of antimycin A, or under high proton motive force, where the
(2Fe2S) cluster may oxidize QH2 to a semiquinone (SQ), but processing
of electrons by the low potential chain is impeded, thus generating the
accumulation of a SQ intermediate, which in turn can reduce O2 to su-
peroxide [18].
The electron transport chain consumes as much as 90% of the oxy-
gen taken up by a cell, of which ~1% is transformed into superoxide
under normal physiological conditions [35]. The rate of mitochondrial
electron transfer from semi-reduced Q to molecular O2 to form super-
oxide is proportional to the product of the semi-reduced Q and O2 con-
centrations. Estimates indicate that under pathophysiological
conditions, superoxide production occurs at 2–10% of the uninhibited
rates. Superoxide dismutases, in turn, generate the more stablehydrogen peroxide before it is transformed into water by catalase or,
if metals are present, into highly reactive hydroxyl radicals. Thus,
SOD2,which directs H2O2 out of themitochondrion, performs two func-
tions: the classical scavenging of superoxide and its signalization as
ROS-dependent signaling pathways. The binding of CO to cytochromes
found in complex IV (i.e., cytochrome a3) enhances reduction in the re-
spiratory carriers in the cytochrome bc1 region of complex III, associated
with increased leakage of superoxide and H2O2 production.
Much of the superoxide produced is efﬁciently converted to hydro-
gen peroxide by the activity of superoxide dismutases that include the
cytoplasmic (SOD1) and mitochondrial (SOD2) enzymatic forms. As
the superoxide is a highly reactive free radical, it can damagemolecules
(DNA, proteins and lipids). Its conversion to hydrogen peroxide there-
fore protects cells, but if Fe2+ or Cu+ are present even in very low con-
centrations, this peroxide can generate hydroxyl radical that induces
membrane lipid peroxidation [36]. Moreover, nitric oxide (generated
in response to activation of the enzyme nitric oxide synthase by Ca2+/
calmodulin) can interact with mitochondrial superoxide to produce
the highly reactive free radical peroxynitrite [37]. Antibodies that selec-
tively recognize proteins modiﬁed by the lipid peroxidation product 4-
hydroxynonenal and by nitration have been particularly useful instru-
ments for detecting and quantifying oxidative damage to proteins,
lipids and DNA [38]. In addition, researchers have made use of ﬂuores-
cent probes for imaging relative levels of overall mitochondrial redox
status and superoxide in order to deﬁne the role of mitochondrial ROS
in a number of physiological and pathological processes [39]. An exces-
sive ROS production is thought to contribute to damaging effects in a
range of diseases such as cancers, cardiovascular disease and inﬂamma-
tory conditions such as arthritis [40]. Neurons may be particularly vul-
nerable to mitochondrial ROS on account of their high energy
demands, excitability, and the fact that they are postmitotic and there-
fore irreplaceable in most cases [64]. On the contrary, lower subtoxic
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tect cells against injury and disease [18,38].
New ﬁndings suggest that modiﬁcations in mitochondrial activity
can induce morphological adaptations of the mitochondrial network.
Moreover, clinical studies indicate that molecular defects affecting
mitochondrial dynamics bring about pathology. This suggests that
there is a link between energy status and organellar network conﬁg-
uration. In this context, a balance between fusion and ﬁssion events,
mediated by speciﬁc proteins that might be involved in the modula-
tion of energy production, occurs controlling mitochondrial conﬁgu-
ration [41]. Physiologically, mitochondria undergo continuous
ﬁssion and fusion (known as mitochondrial dynamics) to generate
smaller organelles or rather elongated structures, respectively
(Fig. 2). During this process of mitochondrial biogenesis, in which
new mitochondria are formed, defective mitochondrial DNA is
repaired by redistributing mitochondria to high energy demand
sites. In neurons, the ﬁssion/fusion proteins, regulated by a mecha-
nism involving large dynamin-related GTPases, maintain mitochon-
drial integrity and ensure that they are present at critical sites such
as the synapse where high concentrations of ATP are required [42].
These proteins include Drp1 and Fis1 that act as ﬁssion proteins,
and Mitofusin (Mfn) and Opa1 that have the function of fusion pro-
teins. Since mitochondria play a critical role in neurons, impaired mi-
tochondrial dynamics is increasingly considered to be a factor in
neurodegenerative disorders such as Parkinson's, Alzheimer's and
Huntington's diseases [43].
Dysfunction in mitochondrial dynamics may be due either to ge-
netic mutations in ﬁssion- or fusion-related genes or to post-
translational changes in the ﬁssion or fusion proteins. Hereditary mu-
tations in the mitochondrial fusion GTPases optic atrophy-1 (OPA1)
and mitofusin-2 (Mfn2) occur in Charcot-Marie-Tooth Disease
(CMT), a peripheral neuropathy characterized by muscle weakness
and axonal degradation of sensory and motor neurons. It is also ob-
served in hereditary motor and sensory neuropathy type VI, clinically
similar to CMT, with the addition of optic atrophy and visual impair-
ment, as well as in Autosomal Dominant Optic Atrophy. In addition,
two proteins, PTEN-induced kinase 1 (PINK1) and Parkin, which are
mutant in familial forms of PD have been reported in association
with increased mitochondrial ﬁssion in Parkinson's disease (PD)
models. Furthermore, mutant huntingtin, the disease-causing protein
in Huntington's disease (HD), alters mitochondrial morphology and
dynamics [43]. Rotenone, a pesticide and inducer of PD symptoms,
and amyloid-β (Aβ) peptide, which has been causally linked to Alz-
heimer's disease (AD), are able to initiate mitochondrial ﬁssion [42].
Post-translational modiﬁcations due to nitrosative/oxidative
stress may be the pathogenic cause of common sporadic cases of neu-
rodegeneration, which seem to stem from intricate interactions of
multiple genes and/or their products with environmental factors.
According to Nakamura et al., three post-translational modiﬁcations
– phosphorylation, sumoylation and ubiquitination – appear to regu-
late mitochondrial ﬁssion and fusion proteins [42]. Protein Kinase A
(PKA, cAMP-dependent protein kinase) phosphorylates Drp1, which
results in a signiﬁcant decrease in GTPase activity and inhibition of
mitochondrial ﬁssion. Interestingly, mitosis-promoting factor (MPF,
Cdk1/cyclin B) phosphorylates Drp1 at Ser585 in rats during mitosis.
Unlike phosphorylation by PKA, Cdk1/cyclin B phosphorylation seems
to stimulate mitochondrial ﬁssion during mitosis. However, phos-
phorylation of Drp1 at different amino acids causes opposite effects
[44,45]. Drp1 regulation also occurs through sumoylation. SUMO1
(small ubiquitin-related modiﬁer-1) interacts with Drp1 and associ-
ates with mitochondria at ﬁssion sites before and after ﬁssion [45].
Over expression of SUMO1 results in mitochondrial fragmentation
and apoptosis. This probably occurs because SUMO1 protects Drp1
from degradation, stabilizing Drp1 and promoting binding to mito-
chondria. Ubiquitination has also been associated with mitochondrial
dynamics [45] since MARCH-V or MARCH5, a mitochondrial outermembrane protein, ubiquitinates Drp1, thus promoting ﬁssion. Final-
ly, the functional link betweenmitochondrial dynamics and apoptosis
is suggested by the fact that Bax and Bak, two pro-apoptotic regula-
tors, interact with mitochondrial ﬁssion and fusion GTPases. Bax asso-
ciates with Drp1 and Mfn2 on mitochondria during apoptosis.
Furthermore, neurons under nitrosative stress exhibit Bax foci on mi-
tochondria undergoing mitochondrial ﬁssion. Inhibition of Drp1 func-
tion delays mitochondrial ﬁssion and is related to Bax foci formation
and neuronal cell death [45].
Another potentially harmful effect of increased ROS levels is chronic
mitochondrial ﬁssion. In an animal model of stroke, nitrosative stress
causes profound mitochondrial ﬁssion in neurons prior to the onset of
neuronal loss and treatment with antioxidants has been shown to re-
duce mitochondrial ﬁssion [45]. Amyloid-beta peptide, possibly a key
mediator of AD pathogenesis, engenders S-nitrosylation and thus
hyperactivation of the mitochondrial ﬁssion protein Drp1. This activa-
tion results in excessive mitochondrial fragmentation, bioenergetic
compromise, and synaptic damage in models of AD [42]. Expression of
Mfn or dominant-negative Drp1 partially prevented mitochondrial ﬁs-
sion and neuronal cell death by nitric oxide, which is known to be large-
ly caspase independent. Another study demonstrated that
mitochondrial ﬁssion in cerebellar granule neurons was enhanced by
oxidative stress and thatMfn2 expressionwas protective [45].Whether
oxidative stress directly regulates the mitochondrial ﬁssion and fusion
GTPases is not yet clear. However, since mitochondrial integrity is es-
sential to cellular homeostasis, when the energetic demand is low, ex-
cess mitochondria are not needed and can generate excessive ROS
[46]. Furthermore, if uncoupled, they can consume ATP, thus their elim-
ination by autophagy is an efﬁcient cytoprotective response. Uncoupled
or unstable mitochondria may release ROS and a number of apoptosis-
promoting factors, including cytochrome c, AIF, SMAC/DIABLO, thus
promoting damage to neighboring mitochondria [47].
Mitochondrial biogenesis is another important event in mitochon-
drial biology. It is a phenomenon that relies on a space and time coor-
dinated synthesis and the import of approx. 1000 nuclear-encoded
proteins, some of which are assembled with mitochondrial-encoded
proteins within newly synthesized inner and outer mitochondrial
phospholipid membranes. Both replication of mitochondrial DNA
and mitochondrial fusion and ﬁssion mechanisms must also be syn-
chronized with these processes [48]. Oral acetylcarnitine supplemen-
tation increases mitochondrial content together with nuclear
transcripts of factors involved in mitochondrial biogenesis (PGC-1α,
NRF-1, TFAM). This event is associated with increased levels of mito-
chondrial transcripts for COX I, ATP6 and ND6, and also 16S rRNA.
This is consistent with the notion that peroxisome proliferator-
activated receptor gamma coactivator 1 alpha (PGC-1α) positively
modulates several genes involved in ROS detoxiﬁcation and in turn
PGC-1α is sensitive to ROS and/or RNS [49]. Acetylcarnitine also by
stimulating the vitagene system, especially HO-1, leads to the produc-
tion of carbon monoxide which, according to the model proposed by
Piantadosi [50], can bind to the reduced heme a3 in the cytochrome c
oxidase complex, thus promoting a parallel increase in superoxide
formation from complex III. Superoxide then induces MnSOD overex-
pression with formation of hydrogen peroxide and signalization of
so-called preconditioning. As signaling molecule H2O2 activates pro-
tein kinase B (Akt), which deactivates glycogen synthase kinase-3β,
allowing the nuclear translocation of Nrf2. Nuclear Nrf2, which
binds to antioxidant response elements in the HO-1, MnSOD, and
NFR-1 gene promoters, ampliﬁes the initial signal and drives the tran-
scription of TFAM and other genes that have promoter binding sites
for NRF-1 [18,37,38,51,52]. These genes play a role in the control of
mitochondrial transcription, protein synthesis, mitochondrial protein
import, and oxidative phosphorylation [52]. This was conﬁrmed by
research demonstrating that acetylcarnitine reversed the age-
related decrease in complex III activity and oxidative phosphorylation
through complexes III and IV, and increased the amount of
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[48]. Of note is the fact that both cytochrome b and aa3 proteins are
encoded by the mitochondrial genome, suggesting that acetylcarni-
tine promotes either mtDNA transcription, the stability of mitochon-
drial mRNA, or mitochondrial protein synthesis [51].
4. Autophagy pathway
Autophagy is a lysosomal pathway for the degradation and recy-
cling of long-lived proteins and organelles, i.e. a kind of ‘self digestion’
cell pathway. During autophagy, cytoplasmic constituents are taken
into double-membraned autophagosomes and delivered to lyso-
somes to be degraded. This process generates nucleotides, amino
acids and fatty acids, which are recycled to be used for ATP generation
and macromolecular synthesis [53] (Fig. 3).
While the unfolding protein response (UPR) regulates the degrada-
tion of smaller units of unfolded or misfolded proteins through chaper-
one transcription, larger aggregates are detoxiﬁed via autophagy.
Autophagy involves the encapsulation of cargo on a double-
membrane vesicle to form the autophagosome. Autophagosomes then
fuse with lysosomes to form the autolysosome where the cargo degra-
dation occurs. Hybrid intermediates, known as amphisomes, are also
formed when autophagosomes fuse with endosomes or MVEs, before
fusing with lysosomes. In eukaryotic cells, the ubiquitin–proteasome
and autophagy–lysosome pathways represent the two principal routes
of protein clearance [53]. Proteasomes mainly degrade short-lived nu-
clear and cytosolic proteins. However, substrates must be unfolded in
order to pass through the narrow pore of the proteasome barrel, so
clearance of aggregated proteins observed in many neurological disor-
ders is excluded [54]. On the contrary, lysosomal-related compartments
are able to degrade substrates such as protein complexes andFig. 2.Mitochondrial dynamics. Role ofﬁssation (Drp1 and Fis1) and fusion (Mfn andOpa1) prote
proteins (B). The phosphorylation of dynamin-related protein (Drp1) by the Protein Kinase A (PK
ylation of Drp1 bymitosis-promoting factor seems to stimulate mitochondrial ﬁssion duringmito
ubiquitin-relatedmodiﬁer-1 (SUMO1) interacts with Drp1 at ﬁssion sites and its overexpression
by the ubiquitination of Drp1 by the humanmembrane-associated RING-CH(MARCH)-V. Finally,
the Bcl-2-associated X protein (Bax) associates with Drp1 and mitofusin (Mfn2) on mitochond
undergoing mitochondrial ﬁssion.organelles. Recent evidence indicates that protein clearance via autop-
hagy is linked to their propensity to aggregate. Since ﬁndings suggest
that a number of different diseases may be caused by aggregate-prone
proteins gaining function mechanisms, attempts have been made to
ﬁnd therapeutic strategies that reduce the levels of this type of proteins,
at either the synthesis or degradation stage [54]. Recent studies suggest
that autophagy has a crucial role in protein quality control, and a clear
function in balancing homeostasis in the nervous system [55]. Notably,
p62 (also termed sequestosome 1) interplays between polyubiquitina-
tion and the autophagy-degradative mechanisms, thus shuttling sub-
strates of the proteasome system. Autophagy is less selective than the
latter mechanism, but recent ﬁndings indicate that it is ﬁnely regulated
and speciﬁc for diverse target organelles, such as mitochondria (mito-
phagy) endoplasmic reticulum (reticulophagy), peroxisomes (pexo-
phagy), ribosomes (ribophagy), granules (crinophagy), and pathogens
(xenophagy). Cytosol, cytoskeleton, nuclei (nucleophagy), and protein
aggregates (aggrephagy) can also be removed by autophagy.
Studies have deﬁned several upstream regulators of autophagy
[53]. The class III PI3 kinase complex, including Beclin-1/Atg6, is in-
volved in the generation of pre-autophagosome structures. The mam-
malian target of rapamycin (mTOR), a nutrient-sensing kinase
complex that controls cell growth and survival, prevents autophagy
during nutrient-rich conditions by inhibiting the Atg1 complex,
which is present in the initiation stages of autophagic activity. Up-
stream activators of mTOR (NF-kB, class I PI3 kinase, Akt and NF-
kB) block autophagy, whereas inhibitors of this pathway such as
PTEN (phosphatase and tensin homologue) induce autophagy. For
this reason, in vivo experiments have shown that rapamycin, a classi-
cal mTOR inhibitor, alleviates neurodegeneration in models of Hun-
tington's disease, associated with reduced neuronal loss, improved
survival and degradation of toxic protein aggregates [55]. Atgins in themitochondrial dynamics (A). Post-translationalmodiﬁcations ofﬁssion and fusion
A) inhibitsmitochondrial ﬁssion decreasing GTPase activity. On the contrary, the phosphor-
sis. Moreover, the activity of Drp1 is regulated by themechanism of sumoylation. The small
leads to mitochondrial fragmentation and apoptosis. Mitochondrial ﬁssion is promoted also
there is evidence of a functional linkbetweenmitochondrial dynamics and apoptosis. In fact,
ria during apoptosis and neurons under nitrosative stress exhibit Bax foci on mitochondria
Fig. 2 (continued).
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organized around two ubiquitin-like conjugation systems. When
Atg12 is activated, it forms a covalent bond with Atg5, which then in-
teracts with other components to form a multimeric complex that
translocates to membranes of early autophagosomes. Alternatively,
LC3 is cleaved and then conjugated to phosphatidylethanolamine
(PE) via Atg7 and Atg3 (another ubiquitin carrier protein (E2)-like
protein), generating LC3-II. The unconjugated LC3-I remains in the
cytosol while the conjugated LC3-II form targets to the autophagoso-
mal membrane after the formation of the active Atg12–Atg5 complex
[56]. Following elongation of the autophagosomalmembrane, cytoplas-
mic proteins and organelles are taken into double-membraned autop-
hagosomes, delivered to lysosomes and degraded [53]. Autophagy is
essential for maintaining neuronal homeostasis and plays a role in
basal elimination of misfolded proteins in the nervous system. Brain
speciﬁc ablation of the autophagy-related genes atg5 and atg7 results
in spontaneous neurodegeneration typical of Alzheimer's and Parkin-
son's disease with pathological features such as neurological/motor
dysfunction, accumulation of poly-ubiquitinated protein aggregates,
neuronal loss and premature death [54]. As in UPR, autophagy is be-
lieved to play a dual role in cell survival or cell death. Autophagic degra-
dation of cellular materials produces amino acids and fatty acids, which
can be recycled for protein synthesis and ATP generation during stress-
ful conditions such as starvation. It can also remove protein aggregates
(which can trigger apoptosis) and damaged mitochondria (source ofapoptotic proteins and toxic ROS), thus becoming a protective mecha-
nism. On the contrary, prolonged autophagy can lead to cell death
through excessive self-digestion or activation of apoptosis. In fact,
there is evidence of prosurvival autophagy in response to starvation,
growth factor withdrawal, ischemia/reperfusion injury, and various
chemotherapeutic drugs [57,58], while autophagic cell death has been
reported in response to hypoxia, oxidative stress, radiation, GF with-
drawal, lipopolysaccharide, overexpression of smARF, and various che-
motherapeutic drugs [57].
5. NFkB signal pathway: cell death vs cell survival
Nuclear factor-κB (NF-κB) is a family of transcription factors that
have a crucial role in inﬂammation, immunity, cell proliferation, de-
velopment, survival and apoptosis. Consequently, NF-κB dysregula-
tion has been implicated in diverse human pathologies ranging from
autoimmune diseases to cancers.
In mammalian cells, the NF-kB/Rel family contains ﬁve members:
RelA (p65), c-Rel, RelB, NF-kB (p50; p105), and NF-kB2 (p52; p100)
[58]. These proteins possess a structurally conserved 300 amino acid
sequence called the REL region, which contains the dimerization, nu-
clear localization, and DNA-binding domains. Three of the family
members, RelA, c-Rel, and RelB, have a transactivation domain at
the C-terminus. NF-kB1/p105 and NF-kB2/p100 are the inactive pre-
cursors of the p50 and p52 proteins, respectively; in an unstimulated
Fig. 3. Autophagy. Autophagy pathway: Role of the Atg proteins in the initiation stages of autophagic activity (Atg1 Complex) and autophagosome formation (Atg12 and LC3) and
subsequent autophagosome-lysosome fusion and autophagosome degradation.
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cessing removes the C terminal inhibitory domains, allowing the
resulting proteins to enter the nucleus [59].
NF-κB is induced by a variety of extra-cellular stimuli such as pro-
inﬂammatory cytokines, bacterial lipopolysaccharides, viral RNA and
DNA via the activation of membrane and cytosolic receptors [60,61].
It is also induced by low and high doses of ionizing radiation and nu-
merous DNA damaging drugs [62,63]. Under normal conditions, NF-
κB is present within the cytoplasm in an inactive state, bound to its
inhibitory protein κB-α (IκB-α). This stimulation initiates an intracel-
lular signaling cascade, resulting in the phosphorylation of IκB-α on
serine residues 32 and 36 by IκB kinase (IKK). Phosphorylation and
subsequent ubiquitination of these residues target IκB-α for degrada-
tion by the 26S-proteasome complex. Once liberated from its inhibi-
tory protein, NF-κB translocates into the nucleus, where it
orchestrates the transcription of a number of cytokines and chemo-
kines, growth regulatory and survival genes [64,65].
NF-κB has been shown to activate, via transcription, the genes
encoding pro-inﬂammatory cytokines [tumor necrosis factor (TNF)-
α, interleukin (IL)-lβ and IL-12], cell adhesion molecules [vascular
cell adhesion molecule (VCAM)-1 and intercellular cell adhesion mol-
ecule (ICAM)-1], inducible nitric oxide synthase (iNOS), cyclo-
oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2) [66,67].
These, together with nitric oxide (NO) derived from iNOS and prosta-
glandin E2 (PGE2) produced by both COX-1 and COX-2, play impor-
tant roles in the pathogenesis of acute and chronic inﬂammation
[68]. The production of reactive oxygen species (ROS) such as hydro-
gen peroxide (H2O2), superoxide and hydroxyl radicals, as well
as peroxynitrite, also contribute to the tissue injury observed during
inﬂammation [68,69]. ROS and peroxynitrite also cause DNAdamage [70,71], which results in the activation of the nuclear en-
zyme poly(ADP-ribose) polymerase (PARP), depletion of NAD+
and ATP and ultimately cell death [70].
It should be noted that pathogenic stimuli like excessive produc-
tion of toxic reactive oxygen and nitrogen species, e.g., the oxidative
stress and nitrosative stresses, and many genotoxic factors activate
nuclear factor kappa beta (NF B) signaling pathways which in turn
stimulates the activation of aging-related genes [72]. The NF B trigger
genes that block the cell death (by apoptosis or necrosis) resulting in
aging of the immune system or “immunosenescence”, muscle atro-
phy, and inﬂammation [73].
Interestingly, the master of inﬂammation, NF-kB signaling, is also
a key player in anti-apoptotic signaling [74,75]. For instance, NF-kB
signaling activates the expression of c-FLIP, Bcl-xL, c-IAP1, c-IAP2,
and XIAP proteins, all well-known inhibitors of apoptosis (IAPs). A
few studies have focused on the effect of aging on the expression of
IAP proteins, e.g.-chromosome-linked IAP (XIAP) level has been
shown to increase in the brain during aging [76].
Additionally, there is considerable interest in the contribution of
NF-κB–mediated chronic inﬂammation in aging. The age-related
“constitutive activation of NF-kB” has been veriﬁed in various tissues
during aging [77]. In mice and rats, NF-kB activity has consistently
been shown to be increased with age and in a variety of tissues, in-
cluding heart, liver, kidney, and brain [78]. In humans, NF-kB protein
concentrations were found to be fourfold higher in elderly human
muscles compared with those of young people [79].
Interestingly, the function of the NF-kB complex can be regulated
by the acetylation and phosphorylation of the p65 component [80].
The acetylation of p65 transactivator protein especially increases the
duration and efﬁciency of the NF-kB transcriptional response and
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deacetylases, such as HDAC3 and SIRT1, can regulate the acetylation
level of p65 protein and reduce the efﬁciency of NF-kB-dependent
signaling [82]. The observations of Adler et al. [83] indicate that this
kind of posttranscriptional NF-kB activation occurs during aging.
SIRT1 is the most-widely studied of the Sirtuins and is known to
regulate the function of several important transcription factors, such
as p53, FoxOs and NF-kB, and is also a mammalian longevity gene
[82]. Yeung et al. [82] were the ﬁrst to show that SIRT1 can interact
with RelA/p65 protein in the NF-kB complex and speciﬁcally deacety-
lates lysine 310, which has been earlier demonstrated to potentiate
the transactivation capacity of the NF-kB complex [81]. Several stud-
ies have indicated that SIRT1 is a potent inhibitor of NF-kB transcrip-
tion [82]. The signaling link between SIRT1 and NF-kB is especially
interesting with respect to aging since according to the articles of
Yeung et al. [82] and Adler et al. [83]. It seems that SIRT1 acts to ex-
tend the lifespan by inhibiting NF-kB signaling. Accordingly, it is pro-
posed that the signaling cascades mediated via Sirtuins and FoxO
represent the life-span extending, anti-aging type of regulation. Ef-
fects of sirtuin overexpression on aging, however, have been recently
re-examined after standardization of genetic background and the use
of appropriate controls both C. elegans and Drosophila suggesting that
although a role for sirtuins in determination of metazoan lifespan
cannot be rule out, but doubt on the robustness of the previously
reported effects of sirtuins on lifespan in C. elegans and Drosophila
are questioned [84,85].
6. Heat shock proteins and neuroprotection
Heat shock response (HSR), in which a set of heat shock proteins
(Hsps) are induced and take a key role in cell repair and protective
mechanisms, represents one possible type of cell stress response
[86,87]. This response is regulated at the transcriptional, translational
and post-translational levels by a family of heat shock transcription
factors (HSFs) that are expressed and maintained in an inactive
state under non-stress conditions. Of the three functionally different
HSFs in humans, HSF type 1 (HSF1) is the principal regulator of the
HSR genes. Its task is to mediate signaling of stress-induced stimuli,
such as elevated temperatures, as well as those involved in develop-
ment and many patho-physiological conditions such as cancer,
ischemia-reperfusion injury, diabetes, and aging [88,89]. HSF1 is gen-
erally found in the cytoplasm as an inert monomer lacking transcrip-
tional activity; both DNA-binding and transcriptional transactivation
domains are repressed through intramolecular interactions and con-
stitutive serine phosphorylation [90]. Upon exposure to heat shock
and other types of stresses, which result in protein damage, HSF1 is
derepressed in a stepwise process that involves oligomerization of
HSF1 monomers to a trimeric state, localization to the nucleus, induc-
ible phosphorylation and sumoylation, binding of nuclear-localized
trimers to DNA, and transcription of HS genes (reviewed in 91). The
main targets for HSF1 are speciﬁc promoter elements composed of re-
peats of the pentameric sequence nGAAn (heat shock elements, HSE)
located upstream of HS genes. High rates of transcription are main-
tained only when HSF1 trimers remain bound to the HSE; when ei-
ther the stress signal is removed or damaged proteins are no longer
generated, the HSR attenuates rapidly, with subsequent conversion
of HSF1 back to the monomeric state [92]. Recent studies have also
shown that inducible acetylation negatively regulates DNA binding
activity [86,93]. Mammalian genomes encode three homologues of
HSF (HSF1, HSF2 and HSF4) regulating HSP expression. HSF1 is be-
lieved to be the paralog responsible for regulating the heat-induced
transcriptional response [86,93], while HSF2 has also been reported
to contribute to inducible expression of heat shock genes through in-
terplay with HSF1 [87]. However, regulation of the mammalian HSR is
a more complex phenomenon than was previously thought. Microar-
ray and chromatin immunoprecipitation analysis, while conﬁrmingthat many known heat-inducible genes have HSF1-binding sites in
their promoters, have identiﬁed another class of genes that recruit
HSF1 to their HSE promoter elements but are not induced by heat
shock [88]. However, these studies have also proven that, in some
cases, HSF1 can also control the expression of genes with non-
chaperone function [94], such as superoxide dismutase, multiple-
drug resistance genes, lactate dehydrogenase, and the T-cell death as-
sociated gene 51 [94]. Neurons appear to be deﬁcient in the heat
shock response while retaining the ability to express such HSF pro-
teins [87]. Furthermore, activation of HSF1 does not occur in motor
neurons even when microinjected with plasmids encoding an HSF1
expression vector, suggesting that the HSF1 signal transduction path-
ways are blocked in these cells [95]. Under non-stress conditions,
HSF1 is repressed by a complex containing Hsp90 and other proteins.
In this inactive state, HSF1 is a monomer that is unable to bind cis-
acting heat shock elements (HSE) in the promoters of HSP genes
[96]. During protein stress and the consequent generation of mis-
folded proteins which displace HSF1 from the inhibitory chaperone
complex, HSF1 trimerizes, becomes phosphorylated and is translo-
cated to the nucleus where it is acetylated and sumoylated before
being able to bind to the heat shock element of Hsp genes [88,94]. Ac-
tivation of HSF1 by heat shock is a multi-step process, involving mul-
tiple inducible phosphorylation, dephosphorylation, acetylation,
deacetylation and sumoylation, which together result in the tran-
scription of HSP genes. Extracellular signal input during heat shock
involves tyrosine phosphorylation upstream of HSF1, involving the
receptor tyrosine kinase HER2 and launching downstream signaling
cascades through intracellular kinase Akt [96]. Akt regulates HSF1 at
least in part through modulating its association with the phosphoser-
ine binding scaffold protein [96].
The inducible expression of heat shock proteins is triggered not
only by thermal stress, but also by environmental redox changes or
exposure to electrophiles which cause trimerization and DNA binding
of HSF1 [89,92], demonstrating that the cysteine redox state is critical
for the activation of this transcription factor. Thus, an intermolecular
disulﬁde bond formation between C36 and C103 within HSF1 induces
trimerization and DNA binding, whereas an intramolecular disulﬁde
bond formation (in which C153, C373 and C378 participate) inhibits
the activity of the transcription factor [97]. Strategies for preventing
damage to brain cells following cerebral ischemia or the progression
of neurodegenerative diseases might be found in the manipulation
of HSR [92]. Hsps are evolutionarily conserved and exist in all cell
compartments [98,99]. Some of the major chaperones (Hsc70,
Hsp90, small Hsps) are present at high concentrations in non-
stressed cells reaching 1–5% of total cellular protein, indicating an im-
portant role for chaperones in cellular homeostasis. Hsps are classi-
ﬁed according to their molecular weight [100]. Hsp70, the 70 kDa
family of stress protein, has been extensively studied and includes
Hsc70 (heat shock cognate, the constitutive form), Hsp72 (the induc-
ible form, also referred to as Hsp72) and GRP-75 (a constitutively
expressed glucose-regulated protein found in the endoplasmic reticu-
lum) [101]. Hsp70s, which are involved in co- and post-translational
folding and the quality control of misfolded proteins [102], partici-
pate in the folding and assembly of newly synthesized proteins into
macromolecular complexes; aggregation prevention; dissolution
and refolding of aggregated proteins; as well as protein degradation
[103–106]. Recent ﬁndings demonstrate that the heat shock response
decreases in aging cells and weakens when the life of organisms is
prolonged beyond the mature adult stage [107]. Cells are no longer
able to activate the transcriptional pathways leading to HSP synthesis.
A decline in protein quality control in neuronal tissues has been
strongly hypothesized, as the etiology of a number of diseases involve
aggregation-prone proteins that form inclusion bodies known to be
linked to pathology. Hsp70 has been extensively associated with the
pathogenesis of misfolding disease [96]. The use of transgenic animals
and gene transfer allowing over-expression of the gene encoding for
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to protection in several different models of nervous system pathology
[22]. Overexpression of Hsp70 and/or its co-chaperones suppresses
huntingtin aggregation and toxicity in yeast and mammalian cell
models of misfolding disease [105]. Increased Hsp70 levels led re-
spectively to reduced aggregation and toxicity of tau and A — two
components associated with Alzheimer's disease [101]. Similarly,
overexpression of Hsp70 reduces toxicity and accumulation of α-
synuclein in high molecular weight and detergent-insoluble deposits
[101]. Increased expression of Hsp70 has been linked to a reduction in
apoptotic cell death, an increase in the expression of the antiapoptotic
protein Bcl-2, a suppression of microglial/monocyte activation, and a
reduction in matrix metalloproteinases. Up-regulation of Hsp70 like-
wise reduced apoptosis and the formation of co-aggregates of the
prion disease protein, PrP [107]. In cases of focal cerebral ischemia,
Hsp70 mRNA is synthesized in most ischemic cells except in areas
blood ﬂow is very low, due to scarce ATP levels. Hsp70 proteins are
produced mainly in endothelial cells, in the core of infarcts in the
cells that are most resistant to ischemia, in glial cells at the edges of
infarcts and in neurons outside the areas of infarction [108–110].
This neuronal expression of Hsp70 outside an infarct might be used
to deﬁne the ischemic penumbras, which means the zone of protein
denaturation in the ischemic areas. Consistently, in in vivo transgenic
mice overexpressing Hsp70, compared to wild-type mice in a middle
cerebral artery occlusion model of permanent cerebral ischemia, it
has been demonstrated that overexpression of Hsp70 reduces the
overall lesion size and also limits the tissue damage within the lesion
[110]. Numerous ﬁndings now point to a correlation between nitrosa-
tive stress mechanisms and Hsp induction. In vitro and in vivo exper-
iments have shown that cytokine-induced nitrosative stress is
associated with an increase in the synthesis of Hsp70 stress proteins
in the brain [111–113]. The molecular mechanisms that control NO-
induced activation of the heat-shock signal seem to be associated
with cellular oxidant/antioxidant balance, maintained principally by
the glutathione status and antioxidant enzymes [61,114–116].
7. Heme oxygenases
Heme oxygenases (HO) are known to be dynamic sensors of cell
oxidative stress and modulators of redox homeostasis throughout
the phylogenetic spectrum. Located within the endoplasmic reticu-
lum, they act together with NADPH cytochrome P450 reductase to ox-
idize heme to biliverdin, free ferrous iron and carbon monoxide (CO).
Biliverdin reductase further catabolizes biliverdin to the bile pigment,
bilirubin [38,107,117,118], a linear tetrapyrrole which has been
shown to effectively counteract nitrosative stress due to its interac-
tion with NO and RNS [37,38,51,119]. Bilirubin is then conjugated
with glucuronic acid and excreted [120]. In the past two decades,
much experimental evidence has demonstrated that bilirubin is an
endogenous cytoprotective molecule. In 1987, Stocker and colleagues
were the ﬁrst to report the antioxidant activity of bilirubin when they
proposed bilirubin as a chain-breaker because it was able to scavenge
peroxyl radicals, transforming into a stable carbon-centered radical
[121]. Later, after observing that bilirubin, in the nanomolar range,
may protect cortical neurons from the toxicity elicited by ~10,000
times higher levels of hydrogen peroxide, Snyder and colleagues
[122], proposed a mechanism based on an ampliﬁcation cycle
whereby bilirubin is oxidized to bilirubin by reactive oxygen species
and then recycled by biliverdin reductase back to bilirubin.
However, the importance of this mechanism of action remains
controversial since only a small fraction of the bile pigments
undergo this redox cycle. Other studies have shown that bilirubin
acts as an endogenous scavenger for both NO and RNS, which
possibly alter the redox status of the cell and generate nitrosative
stress [123]. Although bilirubin possesses these important
antioxidant properties, if produced in excess (e.g. in haemolyticanemia or sepsis), unconjugated bilirubin becomes neurotoxic on
account of multiple mechanisms involving disruption of the cell
membrane structure, reduction of mitochondrial transmembrane
potential and activation of the apoptotic cascade.
Although HO-1 and HO-2 have the same substrate and cofactor
characteristics, the isoforms are encoded by distinct genes, which
share only 43% amino acid sequence homology in humans, and differ
substantially in molecular weight, electrophoretic mobility, tissue
distribution, regulation, and antigenicity [120]. Several stimuli associ-
ated with oxidative and/or nitrosative stress, such as, dopamine ana-
logs, H2O2, hyperoxia, UV light, heavy metals, heme, A
prostaglandins, NO, peroxynitrite, Th1 cytokines, oxidized lipid prod-
ucts and lipopolysaccharide, as well as certain growth factors can in-
duce HO-1 [120,124–127]. HO-1 gene expression, which is controlled
by factors such as pro-oxidant states or inﬂammation [126,127], is
regulated mainly by two upstream enhancers, E1 and E2
[118,119,128]. Both enhancer regions contain multiple stress (or anti-
oxidant) responsive elements (StRE, also called ARE) that also con-
form to the sequence of the Maf recognition element (MARE)
[120,128,129] with a consensus sequence (GCnnnGTA) similar to
that of other antioxidant enzymes [51]. Polymorphisms in the lengths
of GT repeats [11–40] within the HMOX1 promoter appear to be an
important determinant of HO-1 expression and function in humans.
Long GT sequences code for relatively unstable (Z-conformational)
DNA with attenuated transcriptional activity and diminished baseline
and stimulated HO-1 protein expression proﬁles. Short-GT polymor-
phisms which may protect against atherosclerosis-linked conditions
(e.g. coronary artery disease) are accompanied by signiﬁcantly higher
HO-1 activity, whereas the malignant behavior of various neoplasms
is fairly consistently enhanced by the short-GT form [120]. Interest
has focused on the role of HO-1 in AD, a neurodegenerative disorder
involving a chronic inﬂammatory response associated with oxidative
brain injury and Aβ-associated pathology. Signiﬁcant increases in HO-
1 levels have been reported in AD brains associated with neuroﬁbril-
lary tangles. An increase in HO-1 mRNA was also found in AD neocor-
tex and cerebral vessels; the HO-1 increase was also found together
with senile plaques and glial ﬁbrillary acidic protein-positive astro-
cytes in AD brains [120]. The dramatic increase in HO-1 in AD could
be the result of a direct response to an increase in free heme concen-
trations, associated with neurodegeneration, during which brain cells
try to convert the highly toxic heme into the antioxidants CO and bil-
irubin [25]. The protective role played by HO-1 and its products in AD
has focused attention on the possibility of using natural substances
capable of increasing HO-1 levels, as potential drugs for the preven-
tion and treatment of AD. Polyphenolic compounds found in some
herbs and spices, e.g. curcumin, appear promising in this context
[119,130–133]. Curcumin is the active anti-oxidant principle in Cur-
cuma longa, a coloring agent and food additive commonly used in Indian
dishes. This polyphenolic substance can not only inhibit lipid peroxida-
tion and effectively intercept and neutralize ROS and RNS
[124,132,133], but it can also signiﬁcantly increase HO-1 in astrocytes
and vascular endothelial cells [134,135]. Epidemiological studies sug-
gest that curcumin, which is widely used by the Indian population in
nutritional and medicinal compounds, is responsible for a much lower
(4.4- fold) prevalence of AD in India compared to the United States
[132,136,137]. Subsequently, Lim and colleagues have demonstrated
that dietary curcumin given to an AD transgenic APPSw mouse model
(Tg2576) for 6 months reduced indices of inﬂammation and oxidative
damage in the brain of these mice [138]. Further studies indicate that
by inhibiting NFkB activation, curcumin efﬁciently prevents cell death
[139,140].
In the past few years, signiﬁcant progress has been made in deter-
mining the diverse roles of HO-1 in brain senescence, aging-related
human neurodegenerative disorders and other CNS pathologies. Al-
though the acute induction of HO-1 in neural and other tissues has
a predominantly cytoprotective outcome, protracted or repeated
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possibly neurons may continue cellular dysfunction and demise in
many chronic degenerative and neuroinﬂammatory conditions even
when provocative stimuli have ceased [141,142]. In fact increasing
evidence indicates that in normal brain aging, AD, PD, and other se-
nescent neurodegenerations, iron sequestration in tissues, intracellu-
lar oxidative stress and mitochondrial dysfunction may produce
pathogenic momentum that acts downstream from the sustained ac-
tion of HO-1 within the astrocytic compartment. In AD and mild cog-
nitive impairment, immunoreactive HO-1 protein is overexpressed in
the cerebral cortex and hippocampus neurons and astrocytes com-
pared to age-matched, cognitively intact controls and co-localizes to
senile plaques, neuroﬁbrillary tangles, and corpora amylacea. In PD,
HO-1 is markedly over-expressed in astrocytes of the substantia
nigra and Lewy bodies in affected dopaminergic neurons. HMOX1 is
also reported to be up-regulated in glial cells located around human
cerebral infarcts, hemorrhages and contusions, within multiple scle-
rosis plaques, and in other human CNS disorders involving oxidant
degeneration and inﬂammatory conditions. Within this context,
heme-derived free ferrous iron, CO, and biliverdin/bilirubin are all bi-
ologically active substances that can improve or exacerbate neural in-
jury according to the speciﬁc disease conditions. For example, in
‘stressed’ astroglia, HO-1 hyperactivity promotes mitochondrial se-
questration of non-transferrin iron and macroautophagy and may
thereby contribute to the pathological iron deposition and bioener-
getic failure found in most age-related oxidant neurodegenerative
disorders. Glial HO-1 expression may also affect cell survival and neu-
roplasticity through modulation of brain sterol metabolism and pro-
teosomal degradation of neurotoxic protein aggregates [143].
8. Hormesis
In hormesis dose response is characterized by a low dose stimula-
tion and a high dose inhibition. Graphically it can be represented by
either an inverted U-shaped dose response or by a J- or U-shaped
dose response (Fig. 4). The term hormesis ﬁrst appeared in 1943
when Southam and Ehrlich reported that low doses of extracts from
the Red Cider tree enhanced the proliferation of fungi with the overall
shape of the dose response being biphasic. However, it was in fact
Hugo Schulz who demonstrated the occurrence of hormesis experi-
mentally in 1888 [144] by observing biphasic dose responses in
yeast following exposure to a large number of toxic agents. The
work of Schulz encouraged researchers in many different ﬁelds to as-
certain whether such low dose effects were a general feature of bio-
logical systems. In fact, similar types of dose response were
observed by numerous researchers assessing chemicals [145] and ra-
diation [146–157]. Despite the bulk of historical literature on hor-
metic dose responses, this concept was incorporated into routine
safety assessment and pharmacological investigations with difﬁculty,
principally because (i) it required more accurate evaluation in theFig. 4. Dose–response curve depicting the quantitative features of hormesis.low dose zone, (ii) investigators failed to understand its clinical sig-
niﬁcance (iii) the quantitative features of the hormetic dose response
were not appreciated (iv) the limitations of its implications for com-
mercial applications in agriculture as well as medicine were not well
understood (v) during most of the 20th century interest focused on
responses at relatively high doses (vi) there was a continuing, yet in-
appropriate, tendency to associate the concept of hormesis with ho-
meopathy [158–160]. However, after the late 1970s [161,162]
biomedical sciences in general showed a growing interest in
hormetic-like biphasic dose responses due to the possibility of mea-
suring progressively lower doses of drugs and chemicals, the adop-
tion of cell culture methods that allowed more efﬁcient testing of
numerous doses, the need to re-examine the validity of linearity at
low dose modeling of cancer risks as well the astute observations of
independent investigators and their capacity to generalize their ﬁnd-
ings across biological systems [162,163].
These research initiatives undertaken in extremely diverse bio-
medical areas demonstrated that hormetic dose responses are com-
mon and highly generalizable, irrespective of biological model,
endpoints measured and chemical class and/or physical agent studied
[146,154–157,164–166]. This ﬁnding caused surprise in mainstream
branches of toxicology and pharmacology as hormetic responses
were often considered to be paradoxical, not commonly expected
and unreliable because of the lack of capacity for replication. During
the mid decades of the last century, the hormesis concept was largely
absent from the leading toxicological and biomedical textbooks, but
this situation has radically changed as hormesis is now included
into all leading toxicology textbooks (e.g. [166] encyclopedias
[159,167] and other leadingmonographs. In fact, while the terms hor-
metic and hormesis appeared only about 160 times during the entire
decade of the 1980s, in the Web of Science database, in 2010 alone,
these terms were cited nearly 3200 times (Fig. 5).
Observations indicating that these broad ranging dose response
relationships also shared the same general quantitative features
were of further signiﬁcance. More speciﬁcally, the low dose stimula-
tion which is manifested immediately below the pharmacological
and toxicological thresholds is modest in magnitude, being not
more than 30-60% greater than the control group response. The
width of the hormetic stimulation is usually about 10–20 fold starting
immediately from the zero equivalent dose (i.e. estimated threshold).
The hormetic dose response may result from either a direct stimula-
tion or through an overcompensation stimulatory response following
disruption in homeostasis [145,154]. The quantitative features of hor-
metic dose responses are similar, regardless of the way in which stim-
ulation occurs as is conﬁrmed by copious data in the literature
ranging from plants to humans [160,165], and involving numerous
receptor systems [158,168–171]. As a result of these ﬁndings, nearly
60 biomedical scientists have suggested that biological stress re-
sponses, including those of pre- and post-conditioning, should beFig. 5. Citations of Hormesis/Hormetic in Web of Science Database in the period
1981–2010.
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should be based within an interdisciplinary framework [172].
The hormetic dose response requires a different set of interpreta-
tions for the dose response. At high doses within a toxicological set-
ting, the typical endpoints measured indicate cellular damage.
However, as the dose falls below the threshold, the low dose stimula-
tion more likely represents a manifestation of an adaptive response
that conforms to a measure of biological performance visible in mod-
est increases in cognition, growth, longevity, bone density and other
biomedical endpoints of interest.
Since hormetic ﬁndings display broad consistency, this strongly
implies that this dose response may demonstrate the plasticity of bi-
ological systems. That nearly all biological models respond to im-
posed stress with the same quantitative features of the dose
response is a relatively innovative and signiﬁcant ﬁnding within the
biological sciences. These ﬁndings suggest that the hormetic dose re-
sponse would have been broadly selected for and highly conserved.
This adaptive response not only enhances survival by providing resis-
tance to environmental stress, but it also helps to regulate the alloca-
tion of biological resources in a manner that ensures cell and
organismal stability.
These quantitative features of the hormetic dose response have
important medical implications since constraint is imposed upon
the magnitude of a drug to induce a desired effect. For example, if a
drug increased cognitive performance in an elderly patient by ap-
proximately 25–30%, the hormetic model suggests that no further in-
crease in this level could be obtained by using a new drug
combination. Numerous studies on hormesis and drug interaction
have corroborated this concept. Flood [173–176] demonstrated that
the hormetic response for memory was limited to the 30–60% in-
crease even when several drugs were used in combination to maxi-
mize memory outcome. Similar response magnitude constraint has
also been reported for immune stimulation, bacterial growth, in-
creases in hair growth, plant growth, decrease in anxiety, decreases
in tumor incidence and many other endpoints [177].
This limitation in the magnitude of the stimulatory response,
which is documented by extensive ﬁndings, is a critical feature of
the hormesis dose response concept and deﬁnes what pharmaceuti-
cal companies can expect to achieve with drugs designed to enhance
performance. However, the limitation in the magnitude of response is
also potentially important as regards the possibility of detecting a de-
sirable response. Although this may not be an important issue when
using highly inbred animal models or cell cultures where experimen-
tal conditions can be highly controlled, measuring a low dose hor-
metic stimulation in clinical trials can be problematic. Since human
response to a drug can vary considerably, responsiveness of the test
population may be distributed over a range of responses that includes
toxicity, optimal response and a group in which the dose is ineffec-
tive. The data from all subjects in such studies would normally be av-
eraged together leading to a marked dilution of an overall positive
treatment effect in the optimal response zone subgroup. This proba-
bly explains why drugs that were very successfully tested in preclin-
ical studies with highly inbred strains of animals could and often have
failed during the clinical trial. It is of note that investigators may have
to modify doses according to the sensitivity or susceptibility of the
subjects. Calabrese and Baldwin [178] have shown that the hormetic
dose response is often expressed in a broad range of subjects regardless
of their susceptibility. As expected, those individuals that are very resis-
tant to the drug or chemical treatment would have their hormetic re-
sponse shifted to the right on the dose response graph, whereas those
individualswith above normal susceptibilitywould have their hormetic
response shifted to the left. The hormetic dose response therefore pre-
sents considerable challenges for the biomedical community that de-
velops drugs that aim to improve human performance.
The hormetic dose response can also have undesirable effects as
may be most readily seen in the case of drugs designed to suppressgrowth or kill cells or organisms at higher doses. For example, consid-
erable evidence now indicates that low doses of many antitumor
drugs can stimulate the proliferation of such cells at lower concentra-
tions [179]. This also occurs with antibiotics, including penicillin
[180] and streptomycin [180,181]. The same phenomenon has also
been observed with selected cardiac glycosides that have effects on
non-target tissues such as the prostate where it can enhance smooth
muscle cell proliferation by about 30% with clinically relevant doses
[182,183]. However, this 30% increase in prostate smooth muscle
was thought likely to impede urination in males. If the possibility of
the hormetic response is not taken into consideration, this can lead
not only to failure to recognize a desirable drug-induced response,
but it can also result in failure to prevent an adverse effect of drug
treatment.
Since hormetic dose responses have now been widely reported in
biological systems, there is the desire to develop a new subﬁeld of
hormetic mimetics that can activate hormetic pathways in order to
produce a desirable clinical effect without risks associated with expo-
sure as in the case of certain chemical agents and radiation.
8.1. Hormesis and adaptive stress response
The ability to sense oxidative and proteotoxic insults and to coor-
dinate defensive stress response are basic elements for cellular adap-
tation and survival [184]. Over the past decade, an increasing interest
has emerged on the hormetic mechanisms leading to adaptive re-
sponses of cells and organisms to moderate stress [51,185,186].
Mild oxidative or nitrosative stress (characterized by environmental
insults, such as metabolic or physical stress, heavy metals, or patho-
physiological conditions of oxidant-antioxidant balance perturba-
tion), is able to induce the activation of cellular defense signaling
pathways. These are part of a programmed cell life survival setting
and serve to balance more severe stress conditions [51]. Typically,
stressor elicited molecular responses do not only protect the cell
against higher doses of the same agent, but also cross react and func-
tion against other speciﬁc stressors including oxidative, metabolic,
and thermal stress. According to the hormetic principles, low doses
of drugs, toxins, and natural substances may elicit a positive response
in terms of adaptation to or protection from the stressor, whereas at
higher concentration the toxic effect prevails [25,154,187]. The hor-
metic dose–response can occur through different mechanisms: as a
direct stimulatory response; after an initial disruption in homeostasis
followed by the modest overcompensation response; or as a response
to an “adapting” or “preconditioning” dose that is followed by a more
massive challenging dose [51].
Recent ﬁndings have elucidated the cellular signaling pathways
and molecular mechanisms that mediate hormetic adaptive response
which typically involve the synthesis of various stress resistance pro-
teins as the products of “vitagenes”, a group of genes strictly involved
in preserving cellular homeostasis during stressful conditions. The
vitagene family is composed of the heat shock proteins (Hsp) HO
(Heme-oxygenase)-1/Hsp32, Hsp70, Hsp60, by the thioredoxin sys-
tem [22,188,189] and by sirtuin proteins. In this context, as detailed
in the subsequent parafraphs, there is growing evidence that low
concentrations of ROS may be beneﬁcial since they are able to in-
duce the expression of antioxidant enzymes or other defense mech-
anisms, while higher doses may be dramatically deleterious for the
cellular redox homeostasis. Moreover, as an interesting emerging
point of scientiﬁc debate, is the role of exogenous small molecules,
including resveratrol, carnosic acid, sulphoraphane, dymethyl fuma-
rate in activating hormetic mechanisms in response to deleterious
stress conditions, such as during neurodegeneration and cancer
[190,191].
As hormetic paradigmatic cases, they may induce adaptive stress
response at subtoxic doses while may be toxic to mammalian cells
at high concentrations [18]. From a molecular point of view, they
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cluding kinases and transcription factors that induce the expression
of genes that encode antioxidant enzymes, protein chaperones,
phase 2 enzymes, neurotrophic factors and other cytoprotective pro-
teins [22,25,37,190,192,193] (Fig. 6). They resulted also inducers of the
Keap1/Nrf2/ARE pathway. Trascription factor Nrf2 has shown the ability,
both in in vitro and in in vivo experiments, to activate a series of vitagenes,
such as heme-oxigenase-1 (HO-1) [51,119,124,132,134,194–196], coor-
dinately with other cytoprotective proteins [124,195,197–204]. Interest-
ingly, from an hormetic perspective, HO-1 exerts protective role by
degrading the intracellular levels of pro-oxidant heme, producing biliver-
din, the precursor of bilirubin, and carbonmonoxide (CO), molecules
with potent antioxidant-anti-nitrosative and cytoprotective features
at low concentrations [51,111,118,189,205–207]. However, upregu-
lation of HO-1 (i.e., HO/BVR axis) is not always beneﬁcial for cells:
the heme depletion and accumulation of CO and bilirubin it causes
are potentially toxic. Therefore, new pharmacological modulators
of HO/BVR activity must act in a dose-dependent manner. This
would allow dose titration to achieve a desired pharmacologic effect
without producing toxicity. Unfortunately, this goal is more compli-
cated than it seems because toxicity has to be deﬁned in terms of
each of the main products of heme metabolism. Furthermore, sensi-
tivity to the therapeutic/toxic effects of these products is likely to be
tissue- or cell-type speciﬁc. The solution may lie in the use of novel
drug-delivery systems that allow targeted delivery of low doses of
the HO/BVR modulator to selected tissues [208,209]. Consistent to
this notion, biliverdin reductase-A (BVR-A) is emerging as a pleiotro-
pic enzyme involved in cellular stress responses. It not only trans-
forms biliverdin-IX alpha into the antioxidant bilirubin-IX alpha
but through its serine/threonine/tyrosine kinase activity is able to
modulate cell signaling networks. BVR-A's involvement in neurode-
generative disorders such as Alzheimer disease (AD) and amnestic
mild cognitive impairment (MCI) was previously described. Statins
signiﬁcantly increased BVR-A protein levels, phosphorylation and
activity in parietal cortex, which signiﬁcantly correlated with β-
secretase protein levels in the brain, suggesting a possible role for
BVR-A in Aβ formation [210–212]. Thus, a better knowledge of the
vitagene defense network and of the leading hormesis mechanisms
may support the stimulation of various maintenance and repair
pathways through exogenous interventions, such as mild stress or
compounds targeting the vitagene network, as a novel approach to
delay various alterations in cells, tissues and organs and potentially
to prevent and treat many different diseases [25,186].Fig. 6. Vitagenes and the pathway of cellular stress response. Nutritional antioxidants, including
are able to activate vitagenes, such as heme oxygenase, Hsp70, thioredoxin reductase and sirtu
Acetyl-L-carnitine act through the activation of transcription factor Nrf2, which after binding to
TrxR, thus counteracting pro-oxidant conditions. In addition, carnosine has been shown to inhib8.2. Mitostress vs mithormesis and neuroprotection
Recent ﬁndings have revolutionized the previous belief that mito-
chondrial ROS have only a negative impact on cell function and sur-
vival since it is now clear that mitochondrial superoxide and
hydrogen peroxide play important roles in a range of cellular func-
tions and are able to activate signaling pathways that promote cell
survival and disease resistance. Exposure of hippocampal neurons to
subtoxic levels of hydrogen peroxide triggers the release of Ca2+
from the endoplasmic reticulum by causing the opening of both IP3
and ryanodine receptor channels [213]. Interestingly, superoxide en-
hances long-term potentiation of synaptic transmission in hippocam-
pal CA1 neurons by a mechanism requiring activation of ryanodine
receptors and extracellular regulated kinases [214]. Mitochondrial
ROS may also be involved in recovery from injury as superoxide can
stimulate neurite outgrowth by directly activating protein kinase C
[215]. Moreover, peroxynitrite can promote the phosphorylation
and nitration of regulatory sites within receptor tyrosine kinases
thereby activating cell survival signaling pathways including those in-
volving PI3 kinase — Akt and mitogen-activated protein (MAP) ki-
nases [18]. Nitration of proteins involved in synaptic vesicle
trafﬁcking can enhance glutamate release, suggesting that superoxide
and peroxynitrite have a potential role in regulating neurotransmis-
sion [18]. Mitochondrial superoxide production is known to contrib-
ute to neuron damage in pathological conditions such as chronic
cerebral hypoxia or Alzheimer's disease [18]. Nevertheless, abundant
evidence shows that transient neuron exposure to low levels of su-
peroxide which are converted into hydrogen peroxide can protect
them against a subsequent exposure to a level of stress that what
would otherwise have been lethal. This neuroprotective effect due
to a subtoxic increase in cellular oxidative stress is known as “precon-
ditioning” and clearly falls under the paradigm of hormesis [18]. Al-
though studies have revealed the involvement of oxidants in many
signaling pathways, cell strategies for conferring pathway speciﬁcity
to such reactive molecules still requires elucidation. Recent research
suggests that cells may spatially restrict oxidant production to allow
microdomain-speciﬁc signaling [216]. The speciﬁc molecular mecha-
nisms by which mitochondrial ROS elicit hormetic responses in neu-
rons are not fully understood, but recent ﬁndings suggest that
important roles can be attributed to certain transcription factors
with regulatory effects. For example, NF-kB is activated in neurons
in response to oxidative stress and plays a critical part in the adaptive
response that protects neurons against more severe oxidative stress,carnosic acid, resveratrol, sulforaphane, dimethyl fumarate, acetyl-L-carnitine or carnosine
ins which represent an integrated system for cellular stress tolerance. Phytochemicals and
the ARE (antioxidant responsive element) in the HO-1 gene, up-regulates both HO-1 and
it the induction of both HO-1 and Hsp70 following strong nitrosative conditions.
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Bcl-2 [217], TNF also up-regulates the expression of Mn-SOD with an
NF-kB-mediated mechanism, thereby protecting neurons against
excitotoxic, ischemic and oxidative injuries [218]. While mitochon-
drial H2O2 may activate adaptive stress response pathways in neu-
rons, they may also exert a neuroprotective effect by acting on
other cell types in the nervous system. For example, microglial activa-
tion in response to increased oxidative stress can have either positive
or detrimental effects on neurons and neural progenitor cells accord-
ing to the type and amounts of cytokines and growth factors secreted
by the microglia [219]. Oxidative stress can also promote angiogene-
sis in the brain [18], which is of vital importance in restoring normal
neuronal perfusion during the days and weeks after a stroke. This lat-
ter effect is an example of “trans-cellular” hormesis mediated by ROS
[220].
8.3. The neuroprotective effects of hormetic phytochemicals that activate
the KEAP1/NRF2/ARE pathway
An elaborate network of protective mechanisms allows all eukary-
otic organisms to defend themselves against the damaging effects of
oxidants and electrophiles, the principal agents responsible for the
pathogenesis of cancer, atherosclerosis, neurodegeneration, and
aging [221]. Endogenously-formed and exogenously-encountered
electrophiles and oxidants are counteracted by a group of functionally
diverse cytoprotective proteins which are regulated by the Keap1/
Nrf2/ARE pathway (Fig. 7). Based on numerous biochemical studies
and global gene expression proﬁling, it is now evident that the family
of cytoprotective proteins is characterized by extraordinary diversity
and includes: (i) conjugating enzymes (e.g. glutathione S-transferases
(GSTs) and UDP-glucuronosyltransferases); (ii) export pumps (e.g.,
multidrug resistance proteins (MRPs)), (iii) antioxidant enzymes
(e.g., heme oxygenase 1 (HO-1), NAD(P)H:quinone oxidoredctase 1
(NQO1)); (iv) enzymes that participate in the synthesis and regener-
ation of glutathione, the principal small molecule antioxidant in theFig. 7. The Keap1/Nrf2/ARE pathway. Under basal conditions, Keap1 binds and targets transcri
Cullin 3 (Cul3)-based E3 ubiquitin ligase. Under induced conditions, small-molecule inducers c
loses its substrate adaptor function. This leads to increased stabilization of Nrf2, its nuclear tran
tional activation of the expression of cytoprotective genes.cells (e.g., γ-glutamatecysteine ligase, glutathione reductase); (v) en-
zymes that promote the synthesis of reducing equivalents, i.e.,
NADPH (e.g., glucose-6-phosphate dehydrogenase, malic enzyme);
(vi) proteins that do not have enzymatic activities, but possess an
enormous capacity to protect against metal overload (e.g., ferritin);
(vii) enzymes that inhibit inﬂammation (e.g., leukotriene B4 dehydro-
genase); (viii) proteins that participate in the repair and removal of
damaged proteins (e.g., Hsp40, Hsp70, p62 and subunits of the 26S
proteosome) and DNA (e.g., O6-methylguanine-DNA methyltransfer-
ase). The basis for grouping them into one “family” is the fact that
they share common transcriptional regulation, are inducible, and cat-
alyze reactions that, in almost all cases, collectively result in protec-
tion against electrophiles and oxidants, and in enhanced survival
[222–225].
The upstream regulatory regions of the genes coding for cytopro-
tective proteins contain single ormultiple copies of the antioxidant re-
sponse element (ARE, also known as electrophile response element,
EpRE) with the consensus sequence 5′-A/CTGAC/GNNNGCA/G-3′)
[226–231] (Fig. 8). Nuclear factor erythroid 2-related factor 2 (Nrf2),
a basic leucine zipper protein, is the major transcription factor that
binds to the ARE [232]. Activation of transcription requires that Nrf2
binds to the ARE as a heterodimerwithmembers of the smallMaf fam-
ily of transcription factors [233]. Under homeostatic conditions the ex-
pression of cytoprotective genes is low due to the low intracellular
levels of Nrf2 which are maintained by Kelch-like ECH-associated pro-
tein 1 (Keap1) [234]. Keap1 binds to the E3 ubiquitin ligase Cullin3-
RING box1 (Cul3-Rbx1) and presents Nrf2 for ubiquitination and sub-
sequent proteosomal degradation [235–238]. However, the pathway
is activated by various stress conditions (e.g., shear stress, hyperoxia),
and also by many small-molecules (inducers). This activation renders
the cell well-equipped tomeet a subsequent challenge due to the tran-
scriptional upregulation of a large number (more than 100) and ex-
traordinary functional versatility of cytoprotective proteins.
Inducers of the Keap1/Nrf2/ARE pathway belong to ten distinct
chemical classes: (i) oxidizable diphenols, phenylenediamines, andption factor Nrf2 for ubiquitination and proteasomal degradation via association with the
hemically modify speciﬁc reactive cysteine residues (\SH) of Keap1 which consequently
slocation, binding to the ARE (as a heterodimer with small Maf), and ultimately transcrip-
Fig. 8. Structures of some phytochemical inducers of the Keap1/Nrf2/ARE pathway.
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electron-withdrawing groups); (iii) isothiocyanates; (iv) thiocarba-
mates; (v) trivalent arsenicals; (vi) dithiolethiones; (vii) hydroperox-
ides; (viii) vicinal dimercaptans; (ix) heavy metals; and (x) polyenes.
They all have a common property: chemical reactivity with sulfhydryl
groups by oxido-reduction, alkylation, or disulﬁde interchange
[239–243]. It is nowwidely accepted that exogenous and endogenous
inducers chemically modify speciﬁc reactive cysteine residues of
Keap1, which in addition to serving as an adaptor protein for the ubi-
quitination and degradation of Nrf2, also functions as the intracellular
sensor for inducers [224,244]. The cysteine modiﬁcation(s) within
Keap1 result in conformational changes that abrogate its substrate-
adaptor function, ultimately resulting in Nrf2 stabilization, binding
to the ARE and recruitment of the basal transcriptional machinery
to activate transcription of cytoprotective genes (reviewed in
197,199,230,231,245,246).
Many inducers of the Keap1/Nrf2/ARE pathway are natural prod-
ucts. Plants have evolved a versatile array of molecules (phytochem-
icals) with potent activities (i.e., ultraviolet radiation-ﬁltering,
antimicrobial, antifungal, antioxidant) which allow their successful
adaptation and survival in an environment full of challenges, such
as solar radiation, toxins, pathogens and infectious agents. Some of
these phytochemicals (e.g., the phytoalexins) are synthesized de
novo in response to pathogen attack [247]; others (e.g., the isothio-
cyanates) exist as metabolic precursors which are “activated” by en-
zymes that normally are expressed in highly specialized cells and
can only be in direct contact with their substrates following plant in-
jury [248]; yet a third category (e.g., malondialdehyde) has the capac-
ity to potently induce transcriptional upregulation of the plant's own
defense mechanisms [249]. The now compelling evidence for biphasic
dose response effects of environmental “toxins” in biological systems
suggests the possibility that phytochemicals from edible plants might
exert biphasic dose responses and could contribute to the well-
recognized health beneﬁts from plant-rich diets. There are currently
multiple lines of evidence on the protective effects of sulforaphane,
curcumin, and resveratrol, all present in edible plants. Although the
antioxidant activity of certain phytochemicals might be partly re-
sponsible for their health beneﬁts, most people do not consume fruits
and vegetables at quantities that are sufﬁcient to achieve the relative-
ly high concentrations of the antioxidants that are required to scav-
enge free radicals directly. Furthermore, the clinical trials have not
demonstrated beneﬁts of dietary supplementation with antioxidants
such as vitamin E and vitamin C. Emerging evidence suggests that ac-
tivation of the Keap1/Nrf2/ARE pathway, rather than direct free radi-
cal scavenging activity, may better account for the health beneﬁts of
phytochemicals. Indeed, many phytochemicals have been shown to
activate adaptive cellular stress response pathways that induce the
expression of networks of genes encoding antioxidant enzymes, pro-
tein chaperones, neurotrophic factors and other cytoprotectiveproteins. In contrast to direct antioxidants (such as vitamin C)
which have short half-lives, activators of the Keap1/Nrf2/ARE path-
way have long-lasting effects because their action is based on induc-
tion of transcription-mediated signaling [225,250]. Here, we give
examples of some of the most studied phytochemicals that activate
the Keap1/Nrf2/ARE pathway, focusing on their neuroprotective
activities.
8.3.1. Carnosic acid
Compounds with hydroquinone and catechol moieties that are
abundant in plants, activate the Keap1/Nrf2/ARE pathway, and have
been shown to be neuroprotective [251]. In order to activate the
Keap1/Nrf2/ARE pathway, hydroquinones and catechols have to be
oxidized to their corresponding electrophilic quinones [252–254].
As such they can be viewed as “pro-drugs” that are converted to the
ultimate inducers “via the pathological activity that they are intended
to combat” [255]. One catechol-containing phytochemical is carnosic
acid (Fig. 8), a compound found in rosemary (Rosmarinus ofﬁcinalis)
which accounts for 5% of the dry weight of the leaves of this plant
[256]. A recent investigation in rats has demonstrated good bioavail-
ability of carnosic acid following oral administration [257]. Treatment
of cells with carnosic acid was reported to cause chemical modiﬁca-
tion of cysteine residues of Keap1 and induce Nrf2-dependent
genes, resulting in protection of neurons against oxidative stress
and excitotoxicity [258]. The same study showed that carnosic acid
crosses the blood–brain barrier, increases the level of reduced gluta-
thione in the brain of C57BL/6 mice, and protects against middle cere-
bral artery ischemia/reperfusion. A subsequent study in murine
hippocampal HT22 cells conﬁrmed the role of increased glutathione
levels in the neuroprotective mechanisms of carnosic acid [259].
This catechol was also shown to induce expression of the neurotro-
phin nerve growth factor (NGF) promoting neurite outgrowth and
differentiation [260]. Most recently, it was reported that enhanced
expression of nerve growth factor by carnosic acid also occurs in nor-
mal human astrocytes, and that this induction is dependent on activa-
tion of Nrf2 [261]. Increased brain neurotrophin levels were also
observed following intranasal administration of carnosic acid to Spra-
gue–Dawley rats [262].
8.3.2. Sulforaphane
The isothiocyanate sulforaphane (1-isothiocyanato-(4R)-
methylsulﬁnyl)butane) (Fig. 7) is one of the most potent naturally
occurring inducers of the Keap1/Nrf2/ARE pathway. Sulforaphane
was isolated from extracts of the commonly consumed cruciferous
vegetable broccoli (Brassica oleracea) based on its ability to induce
the classical Nrf2-target gene NQO1 [263]. In the nearly 20 years
subsequent to its discovery, the protective effects of sulforaphane
have been demonstrated in various cell culture systems and animal
models. Thus, sulforaphane treatment caused Nrf2 activation and upre-
gulated Nrf2-dependent gene expression in astrocytes [264–267]. This
activation resulted in protection against the damaging effects of tran-
sient exposure to O2 and glucose deprivation [266], aswell as of the tox-
icities of hydrogen peroxide and glutamate, and only in cell cultures
isolated from wild-type, but not Nrf2-knockout animals [265]. Re-
introduction of Nrf2 restored both the upregulation of Nrf2-
dependent genes and the neuroprotection, implying activation of Nrf2
as the mainmechanism of protection [265]. Importantly, the neuropro-
tective effects of this isothiocyanate are long-lasting: following sulfo-
raphane exposure of astrocytes for 4 h the levels of NQO1 and HO-1
mRNA remained elevated for 24 h, and the protein levels for at least
48 h; repeated exposures resulted in even further accumulation of
NQO1 and sustained protection against oxidative stress [267]. In dorsal
root ganglion neurons, sulforaphane treatment caused Nrf2 nuclear
translocation and upregulation of the activities of GST and NQO1
[268]. In rat organotypic nigrostriatal cocultures, sulforaphane pro-
tected against the toxicity of 6-hydroxydopamine [269]. Similarly,
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anewere observedwhen primarymurine cortical neuronswere treated
with the endogenous neurotoxin S-S-cysteinyl dopamine; protection
was dependent on induction of Nrf2-dependent genes, and also,
on activation of ERK1/2 and PI3K/Akt signaling [270]. Cultured em-
bryonic hippocampal neurons were also protected by sulforaphane
against the toxicities of hemin or of exposure to oxygen in combi-
nation with glucose deprivation [271]. In motor neurons grown in
organotypic cultures of rat spinal cord, sulforaphane reduced extra-
cellular accumulation of glutamate and protected against glutamate-
mediated excitotoxicity caused by threohydroxyaspartate [272].
Kainate-induced cell death was reduced upon treatment with sulfo-
raphane in hippocampal slices of wild-type, but not Nrf2-knockout
mice [273]. When mitochondria were isolated from brain of Fischer
344 rats that had been treated with sulforaphane (10 mg/kg, i.p.,
40 h prior to isolation of mitochondria), they were found to be
more resistant to oxidative stress-induced Ca2+-dependent perme-
ability transition pore opening than brain mitochondria from control
animals [274].
Administration of sulforaphane (5 mg/kg, i.p.) to Long–Evans rats,
increased the levels of HO-1 mRNA and protein in brain; increases
were detected in both neurons and astrocytes [194]. In a model
of focal cerebral ischemia, when sulforaphane was administered
15 min after the onset of ischemia, the infarct volume (evaluated
3 days later) was reduced by ~50% [194]. In a model of traumatic
brain injury in Sprague–Dawley rats, sulforaphane administered 6 h
post-injury attenuated the loss of the water channel aquaporin-4
(AQP4) in the injury core and increased the levels of AQP4 in the pen-
umbra region [275]. In a subsequent study, a similar treatment with
sulforaphane reduced the blood–brain barrier permeability and the
loss of endothelial cell markers and tight junction proteins, and pre-
served the blood–brain barrier function [195]. The protective effects
of sulforaphane were also evident in C57BL/6 wild-type mice, but
not in Nrf2-knockout animals, implicating activation of Nrf2 as the
underlying mechanism of protection.
In a model of intracerebral hemorrhage in Sprague–Dawley rats,
sulforaphane induced Nrf2-dependent genes and reduced markers
of oxidative damage in the perihematoma area [202]. Three
days following intracerebral hemorrhage, in the sulforaphane-
treated animals, the perihematoma neutrophil count and the total
hemorrhage-affected striatum neutrophil count were reduced com-
pared to the same parameters in control animals. Importantly,
10 days after the hemorrhage, the neurologic deﬁcits were substan-
tially reduced in the sulforaphane-treated animals. In close agree-
ment with the traumatic injury model, Nrf2-knockout animals had
exacerbated neurologic deﬁcits than wild-type mice, and the pro-
tective effects of sulforaphane were lost. Interestingly, sulforaphane
was also shown to increase the levels of haptoglobin in oligoden-
droglia correlating with reduction in brain damage following intra-
cerebral hemorrhage [276]. Haptoglobin which is synthesized in the
brain is important for protecting neurons and oligodendrocytes
against damage caused by intracerebral hemorrhage as it binds
and neutralizes hemoglobin that could otherwise cause cytotoxici-
ty. Sulforaphane treatment (5 mg/kg, i.p., administered at 0.5, 12,
and 36 h following blood injection) was recently reported to reduce
brain edema, cortical apoptosis, blood brain barrier impairment,
and motor deﬁcits in a model of early brain injury after subarach-
noid hemorrhage in Wistar rats [277].
In another study of traumatic brain injury, sulforaphane treatment
caused activation of Nrf2 and upregulation of Nrf2-dependent genes,
whereas there was reduction in oxidative damage, neuronal death,
contusion volume, and neurological deﬁcits [278]. Compared to
wild-type, Nrf2-knockout mice showed greater severity of damage
and were not protected by the sulforaphane treatment [279]. In addi-
tion to its immediate beneﬁcial effects, sulforaphane treatment was
also shown to improve long-term cognitive function followingtraumatic brain injury; however, this improvement only occurred
when sulforaphane was administered 1 h, but not 6 h, post-injury
[279]. In a rat model of neonatal hypoxic-ischemic injury evoked by
carotid artery ligation and hypoxia, sulforaphane administration
30 min prior to injury activated Nrf2 and reduced oxidative stress
markers and the infarct size in the brain [280].
Notably, sulforaphane, and inducers of the Keap1/Nrf2/ARE pathway
in general, also have anti-inﬂammatory properties. Thus, in primary co-
cultures of rat microglial and astroglial cells sulforaphane induces Nrf2-
dependent genes and attenuates LPS-stimulatedproduction of TNFα, IL-
1β, IL-6 and NO [281]. In C57BL/6 mice that received endotoxin injec-
tion, sulforaphane treatment decreased microglial activation and the
upregulation of inﬂammatory markers (iNOS, IL-6, and TNF-α) [282].
Compared to wild-type, Nrf2-knockout mice were hypersensitive to
LPS-induced neuroinﬂammation, strongly suggesting that even the
basal expression of Nrf2-dependent genes provides protection. In the
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkin-
son's disease, sulforaphane protected nigral dopaminergic neurons
against cell death, reduced astrogliosis, microgliosis, and release of
pro-inﬂammatory mediators in basal ganglia; in contrast to wild-type
mice, no protection by sulforaphanewas observed inNrf2-knockout an-
imals [283–285].
Similarly to the damaging effects ofmicrogliosis to the brain, spinal
cordmicroglia activation following peripheral nerve injury also causes
tissue damage. Intrathecal administration of sulforaphane was shown
to activate Nrf2 in the spinal cord, markedly reduce oxidative stress
and pro-inﬂammatory cytokine expression caused by spinal nerve
transection, and to inhibit the development of neuropathic pain
[286]. Very recently, two studies reported the neuroprotective effects
of post-injury treatment with sulforaphane in spinal cord injury
models in Fischer rats and ICR mice; again, it is clear that both induc-
tion of Nrf2-dependent genes and anti-inﬂammatory activity play
critical roles in the protective mechanism(s) [287,288].
Sulforaphane, through the Nrf2-dependent upregulation of cyto-
protective proteins, also has the potential to accelerate the metabo-
lism and elimination of neurotoxic chemicals. Thus, sulforaphane
treatment before exposure to methylmercury decreased mercury ac-
cumulation in the brain and liver of wild-type, but not Nrf2-knockout
mice most likely by facilitating the metabolism and excretion of
methylmercury [289]. Indeed, studies in primary hepatocytes showed
that exposure to sulforaphane led to activation of Nrf2, causing upre-
gulation of γ-glutamatecysteine ligase (and consequently increased
levels of GSH), GSTA1, and MRP2, thus reducing mercury accumula-
tion and cytotoxicity [289].
8.3.3. Dimethyl fumarate
Fumaric acid is found in shepherd's purse (Capsella bursa-pastoris), a
cruciferous weed which is used as a traditional herbal medicine. Before
the discovery of Nrf2, it had been shown that inclusion of the methyl
ester of fumaric acid, dimethyl fumarate (Fig. 8), in the diet of CD-1
mice and Sprague–Dawley rats elevated the activities of GSTs and
NQO1 inmany organs [204,290]. In primary co-cultures of ratmicroglial
and astroglial cells, dimethyl fumarate induced Nrf2-dependent genes,
and lowered the LPS-induced formation of TNF-α, IL-1β, IL-6 and NO
[281]. In a model of chronic experimental autoimmune encephalomy-
elitis in C57BL/6 mice, dimethyl fumarate treatment increased blood
levels of IL-10 and lowered macrophage inﬁltration in the spinal cord
[291]. Orally administered dimethyl fumarate to mice increased Nrf2
positivity in neuronal subpopulations in the striatum and the motor
cortex in models of Huntington's disease; Nrf2 activation correlated
with preservation of morphologically intact neurons in these areas
[292]. In a model of multiple sclerosis, dimethyl fumarate upregulated
NQO1 activity in liver and cerebellum and had protective effects on ol-
igodendrocytes, myelin, axons and neurons [293]. In a model of exper-
imental autoimmune encephalomyelitis, dimethyl fumarate increased
Nrf2 levels in oligodendrocytes, astrocytes, and in neurons of the
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Nrf2-knockout mice had exacerbated pathology, and the beneﬁcial ef-
fects of dimethyl fumarate were lost [293]. Because fumaric acid salts
and esters are already used as therapeutic agents [294–296], human
studies have been recently conducted in patients with relapsing-
remitting multiple sclerosis. In a pilot study, oral dimethyl fumarate re-
duced the formation of new inﬂammatory lesions [297]. These encour-
aging results were further conﬁrmed and extended in a multicentre,
randomized, double-blind, placebo-controlled, dose-escalation, Phase
IIb clinical trial [298]. Currently, dimethyl fumarate is in a Phase III clin-
ical trial [299].
8.3.4. Resveratrol
Resveratrol (3,5,4′-trihydroxy-trans-stilbene) (Fig. 8) was identi-
ﬁed as the active principle of an extract derived from a nonedible Pe-
ruvian legume (Cassia quinquangulata Rich.) in an activity-guided
fractionation based on its ability to inhibit cyclooxygenase; in the
same study, it was also found to induce the classical Nrf2-
dependent enzyme NQO1 in Hepa1c1c7 cells, and, remarkably, to be
able to inhibit the process of carcinogenesis at all of its stages [300].
Resveratrol is present in more than 70 plant species. Its quantity is es-
pecially high in grapes (50–100 μg of resveratrol per gram of fresh
grape skin) and red wine [300,301]. There are currently more than
4000 publications on resveratrol, demonstrating the phenomenal
amount of scientiﬁc interest fueled by the extraordinary broad spec-
trum of biological activities that have been attributed to this phyto-
chemical [302].
One very widely-used experimental model demonstrating the
neuroprotective effects of resveratrol is the rat pheochromocytoma
cell line PC12. Thus, exposure of PC12 cells to resveratrol has been
shown to cause activation of Nrf2 and upregulation of HO-1 [273],
and to protect against the toxicities of hydrogen peroxide [196,303],
β-amyloid [303,304], ethanol [305] oxidized lipoproteins [306,307],
4-hydroxy-2-nonenal [308], oxygen-glucose deprivation [309], and
the combination of Fe2+ and t-butyl hydroperoxide [310]. Further-
more, in PC12 cells that express α-synuclein under the control of an
inducible promoter, resveratrol activated the AMPK/SIRT1 pathway,
induced autophagy and enhanced the degradation of α-synuclein
[311]. Additionally, resveratrol was reported to inhibit the polymeri-
zation of β-amyloid in vitro [312]. In cultured dorsal root ganglion
neurons, resveratrol treatment caused Nrf2 nuclear translocation
and upregulation of the activities of GST and NQO1 [268]. Resveratrol
increased glutamate uptake and intracellular glutathione levels, and
protected against the toxicity of hydrogen peroxide in C6 astroglial
cells, primary astrocytes and hippocampal slices [313–315]. In
human neuroblastoma SH-SY5Y cells, resveratrol induced autophagy
and protected against rotenone-induced apoptosis [311].
In a Drosophilamodel of Huntington's disease, resveratrol activated
ERK [316] and suppressed neurodegeneration [317]. Neuroprotection
by resveratrol has also been demonstrated in in vivo models of Alzhei-
mer's disease and Parkinson's disease, with activation of SIRT1 being
implicated as the protective mechanism (reviewed in 318). In a rat
model of spinal cord injury, resveratrol improved functional recovery,
reversed the spinal cord injury-induced decrease in activity of superox-
ide dismutase, and reduced the levels of markers of oxidative stress
(malondialdehyde), inﬂammation (TNF-α, IL-1β, and myeloperoxi-
dase), and apoptosis (caspase-3) [319]. In several othermodels of spinal
cord injury, resveratrol protected against oxidative stress (as evidenced
by lower malondialdehyde, nitric oxide, xanthine oxidase, and higher
glutathione levels), reduced tissue injury, and improved neurological
recovery [320–323]. Reduction in infarct volume and neuroprotective
effects of resveratrolwere also seen in rats subjected to focal cerebral is-
chemia injury [324,325]. Another study of cerebral ischemia injury
reported that resveratrol treatment improved neurological scores and
reduced infarct volume and brain water content [326]. The levels of
malondialdehyde were lower in the resveratrol-treated animas,whereas the activity of superoxide dismutase was restored. These ef-
fects were accompanied by Nrf2 activation, upregulation of HO-1, and
downregulation of caspase-3. A recent investigation using a rat model
of fetal alcohol spectrum disorders also reported the Nrf2-dependent
protective effects of resveratrol: the authors found that ethanol in-
creased the levels of oxidative stress and inhibited the activation of
Nrf2 in the cerebellum; administration of resveratrol prior to ethanol
exposure restored the levels and the DNA-binding activity of Nrf2 and
the expression of its downstream cytoprotective proteins NQO1 and
SOD, increased the levels of reduced glutathione, reduced oxidative
stress, and enhanced survival of cerebellar granule neurons [327].
It is becoming increasingly apparent that the neuroprotective ac-
tivities that have been attributed to the phytochemicals discussed in
this section in a great number of experimental systems are due to
the fact that they are not single-target agents, but quite the opposite:
all of these molecules have the ability to affect numerous cellular com-
ponents and processes. It is also clear that many of these diverse pro-
tective effects can be attributed to the capacity to these molecules to
mobilize endogenous defense mechanisms by providing two major
triggers: (i) activation of transcription factor Nrf2-mediated gene ex-
pression, and (ii) suppression of pro-inﬂammatory responses. It is
then the ability of the cell to mount and orchestrate its own versatile
protective responses that determines its successful adaptation and
survival.
8.4. A focus on the hormetic role of resveratrol
Due to its remarkably broad range of effects, including mostly an-
tioxidant and anti-inﬂammatory activities, immunomodulation, che-
moprevention, cardiovascular protection and longevity, resveratrol
has attracted numerous researchers investigating the hormetic mech-
anisms underlining its biological responses in cells and organisms
[168]. The emerging body of evidence indicates that the wide range
of resveratrol induced end-points displayed a biphasic dose response
with quantitative features consistent with the hormetic relationship.
Interestingly, many in vitro studies demonstrated the resveratrol
ability to hormetically induce and inhibit cell proliferation in numer-
ous human cancer cell lines, at low and high concentrations, respec-
tively. Several cell lines were affected, such as breast [328–335],
prostate [336–339], leukemia [340,341], colon [342,343], uterus
[344], and lung [345] tumor cell lines. These results suggest that res-
veratrol may prevent or enhance tumor development, according to
the extent of the dose applied. It is a crucial point of discussion in con-
sideration of both the relevance given to resveratrol potential chemo-
preventive effects, to the implications that resveratrol dietary amount
may have for human health and the potential therapeutic dose man-
agement [168,334].
Similarly a consistent hormetic biphasic dose–response relationship
was detected by Gu et al. [346] for endothelial human cell proliferation,
and also for cell migration, as well as cell adherence and eNOS expres-
sion/concentration in injured arteries. These in vitro ﬁndings were sup-
ported also in subsequent in vivo studies with a rat model. Such studies
demonstrated that a low dose of resveratrol enhanced the mobilization
of endothelial cells, facilitated re-endothelialization, reduced the occur-
rence of neointimal formation and up-regulated the expression of eNOS
following an induced balloon injury. These ﬁndings were not only sup-
ported in subsequent research of Xia et al. [347]which corroborated the
hormetic-like response of resveratrol on endothelial progenitor cell pro-
liferation and cellmigration, but further extended other observations by
linking these responses to telomerase activity via AKT-dependent
mechanisms. As in the case of the endothelial cell parametersmeasured,
the resveratrol-induced alterations in telomerase activity were also in-
dicative of hormetic responses.
Szende et al. [342] demonstrated that resveratrol biphasically af-
fected proliferation with a low-concentration stimulation and a
high-concentration inhibition in human endothelial cells. Using
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resveratrol biphasically affected endothelial cell migration. While the
authors acknowledged the capacity of resveratrol to induce a biphasic
concentration response, they emphasized that their data revealed
that high concentrations of resveratrol might have utility as a potent
anti-angiogenesis drug. However, at lower concentrations, the re-
sponse could switch to angiogenic effects.
Resveratrol has anti-inﬂammatory properties such as shown with
the inhibition of COX-1 [300] and COX-2 [349], down-regulation of
prostaglandin biosynthesis and suppression of carrageenan-induced
paw edema [300,350]. Since these collective ﬁndings suggested a pos-
sible effect on immune response, Falchetti et al. [351] explored, in de-
tail, the effects of resveratrol on multiple immune functions of human
T-cells in vitro. These included the development of cytokine-
producing CD4+ and CD8+ T cells by stimulating peripheral blood
mononuclear cells (PBMC) with anti-CD3/antiCD28, speciﬁc
antigen-induced generation of cytotoxic T lymphocytes and natural
killer (NK) activity of peripheral blood mononuclear cells. These au-
thors reported that there was a hormetic-like biphasic dose response
for each endpoint assessed. According to Falchetti et al. [351] these
ﬁndings suggested a regulatory effect of resveratrol on the immune
response. Gao et al. [352,353] revealed that resveratrol inhibited the
Con A induced proliferation of the spleen cells but only at high con-
centrations. At lower concentrations, the proliferative response was
signiﬁcantly increased. These ﬁndings generally supported the con-
clusion that resveratrol has the capacity to suppress or upregulate im-
mune response depending on the concentration.
Interestingly, a 2005 study by Juan et al. [354] provided such a
mechanistic insight into how resveratrol affects a hormetic response
in human aortic smooth muscle cells (HASMCs). Resveratrol induced
HO-1 expression in a manner that conformed to the hormetic dose re-
sponse, markedly enhancing HO-1 expression at low concentrations
whereas at higher concentrations, this response was diminished. Res-
veratrol induction of the HO-1 gene was mediated via the NF-kB
pathway. In fact, two separate NF-kB inhibitors abolished the capacity
of resveratrol to induce HO-1 expression and the activity of the HO-1
promoter. Low concentrations of resveratrol enhanced NF-kB-binding
activity based upon experiments assessing electrophoretic mobility
shifts. At these low concentrations, the resveratrol trans-activated
the NF-kB and this activation process enhanced the transmigration
of NF-kB into the nucleus, which then led to the modulation of HO-
1 gene expression.
It was demonstrated also that resveratrol had chemopreventive
effects with respect to several conditions such as cardiovascular dis-
ease [355], Alzheimer's disease [304], osteoporosis [356] and gastric
ulcers [357]. From a hormetic perspective, in these conditions, low
doses of resveratrol were shown to confer protection whereas higher
doses showed adverse health effects. However, in relation to digestive
disorders, there are contradictory results that identiﬁed resveratrol as
a beneﬁcial agent at different doses, without detecting any biphasic
dose responses [358].
Various parasitic diseases were also hormetically inﬂuenced by
resveratrol. Animal models showed that elevated doses protected
against Leishmaniasis and Trichinella, while low concentrations con-
sistently enhanced their proliferation [359,360].
Globally viewing, low concentrations of resveratrol can be poten-
tially beneﬁcial or harmful, depending on the endpoint investigated.
In this regard, low doses of resveratrol would have the capacity to in-
crease the risk of tumor development of a number of organs and in
contrast to be signiﬁcantly cardio-protective. This type of conﬂict be-
tween beneﬁcial or harmful effects is not uncommon and it is maybe
related to the different biological system, tissue and chemical agent
investigated.
Resveratrol is probably the most studied molecule of a series
of phytochemicals, including sulforaphane, curcumin, fumaric acid
and other chemicals (as previously detailed), that, as hormeticparadigmatic cases, may induce adaptive stress response at subtoxic
doses while may be toxic to mammalian cells at high concentrations
[18]. However, even if the evidence regarding the hormetic dose–
response induced by resveratrol is quite strong, the molecular mecha-
nisms underlining this phenomenon, at present, are not fully under-
stood and deserve greater attention in future research. Moreover,
future studies should be focused in putting the ﬁndings described into
a realistic biological framework to determine whether or not these ef-
fects are relevant for human health [361].
8.5. The potential hormetic role of carnitine and carnosine
In the ﬁght against oxidative and nitrosative stress, a great scien-
tiﬁc interest has been attracted by the ability of the natural peptides
L-carnitine (and its acyl-carnitine ester, Acetyl-L-carnitine (ALC)
(Fig. 9), and carnosine (Fig. 9) to decrease cellular oxidative stress, as-
sociated with aging, improving mithocondrial bioenergetics, scaveng-
ing radicals or functioning as proton buffers and metal chelators
[25,362,363].
Although, as previously described for the phytochemicals, the an-
tioxidant activity of these molecules might be partly responsible for
their health beneﬁts, recent ﬁndings support the activation of a series
of vitagene pathways such as networks of genes encoding antioxidant
enzymes, protein chaperones, neurotrophic factors and also the acti-
vation of the Keap1/Nrf2/ARE pathway as leading cytoprotective
mechanisms [225,250].
The emerging evidence for biphasic dose response effects of envi-
ronmental “toxins” in biological systems and the analog mechanisms
of action demonstrated for phytochemicals, carnitine and carnosine
suggests the possibility that these latter exert their function accord-
ing to a biphasic dose response relationship.
8.5.1. Carnitine
L-Carnitine (LC) is a nonessential nutrient ﬁrst described in the
beginnings of the 20th century [364]. Mammals can synthesize LC in
the liver, kidney and brain from two essential amino acids, lysine
and methionine [365,366]. In humans, 75% of the total body carnitine
comes from dietary sources, particularly red meat and dairy products
[367]. L-Carnitine main role is in cellular energy metabolism. It has
two major functions: (1) transport of long-chain fatty acids in the
form of acylcarnitines from the cytosol into the mitochondria for
their subsequent use as a source of energy (via acetyl-CoA formation
in the process known as β-oxidation) and (2) the removal of short-
and medium-chain fatty acids formed as a consequence of normal
metabolism, preventing a toxic accumulation of these compounds in
the mitochondria and leading to an increase of free CoA. In this con-
text, L-Carnitine is essential in the equilibrium between acetyl-CoA
(plus carnitine) and CoA (plus acetylcarnitine) (acetyl-CoA/CoA
ratio) which is crucial for mitochondrial metabolism.
Both a decline in mitochondrial energetics and an increase in oxi-
dative stress are some of the effects of aging. Regarding the oxidative
insult, in vitro experiments reported antioxidant properties of acetyl-
carnitine mediated by its iron chelating properties [368]. Compara-
tively, as a cellular antioxidant defense mechanisms, ALC decreased
brain lipid peroxidation in old rats [369]. ALC may also prevent the
age-associated changes to proteins. Oxidative modiﬁcation to pro-
teins appears to increase with age, as evidenced by increased levels
of protein carbonyls, 3-nitrotyrosine and 4-hydroxynonenal [370].
Supplementing ALC to the older rats decreased many of these param-
eters in most of the brain regions investigated [370,371]. Pre-
treatment of cortical neurons with ALC signiﬁcantly reduced the
HNE-associated cytotoxicity, protein and lipid oxidation, and apopto-
sis in a dose-dependent manner as well as increased cellular reduced
glutathione and Hsps as compared to controls [372,373]. ALC treat-
ment also leads to the activation of phosphoinositol-3 kinase (PI3K),
PKG, and ERK1/2 pathways that are important in neuronal cell
Fig. 9. Chemical structures of the L-carnitine, acetyl-L-carnitine and L-carnosine.
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against lipid peroxidation and membrane breakdown [374,375]. In
streptozotocin-induced diabetic rats, treatment with ALC improved
nerve conduction velocities (the speed of signal through the nerves),
and this was associated with a reduction in elevated malonyldialde-
hyde (MDA) content, an indicator of lipid peroxidation [376]. When
administered via the perfusate to ischemia-reperfused rat hearts, car-
nitine derivatives were able to scavenge peroxyl or superoxide radi-
cals [377].
As an ulterior conﬁrm of the ALC stimulated endogenous cellular
antioxidant defense, treatment of astrocytes with acetylcarnitine in-
creased the amount and activity of heme oxygenase-1 (HO-1) [378].
In addition, pre-incubation of astrocytes with acetylcarnitine before
the initiation of a nitrosative stress with lipopolysaccharide and inter-
feron, prevented the decrease in complex IV activity, protein nitration
and restored the reduced glutathione/oxidized glutathione ratio
[378].
One of the mechanisms responsible of the decrease in oxidative
stress is the protective effect of ALC on mitochondrial structure and
function. ALC has been considered as a mitochondrial nutrient that
protect mitochondrial dysfunction by different mechanisms, such as
preventing oxidant production or scavenging free radicals (processes
that prevent oxidative stress in mitochondria); enhancing mitochon-
drial antioxidant defenses; enhancing mitochondrial metabolism to
facilitate both the repair of less damaged and the degradation of
more damaged mitochondria, and protecting mitochondrial enzymes
and/or stimulating enzyme activity as enzyme substrates and cofac-
tors [379]. In this regard, pretreatment of pancreatic β-cells with mi-
cromolar concentrations of acetylcarnitine was demonstrated to
protect the cells from oleic acid-induced mitochondrial dysfunction
and decrease ROS production [380]. ALC increased hepatocellular ox-
ygen consumption and partially reversed the decrease in mitochon-
drial membrane potential associated with aging, while reducing
MDA levels and restoring hepatocellular ascorbate levels [362]. A re-
cent study showed that acetylcarnitine reversed the age-related de-
crease in the activity of complex III and oxidative phosphorylation
through complexes III and IV and increased the amount of cyto-
chrome b and aa3 hemes in cardiac mitochondria isolated from old
rats [381]. Of interest, both cytochrome b and aa3 proteins are
encoded by the mitochondrial genome, suggesting that acetylcarni-
tine enhances either mtDNA transcription, the stability of mitochon-
drial mRNA, and mitochondrial protein synthesis. ALC has been
demonstrated to improve mitochondrial respiration in neurons and
to be neuroprotective through a variety of other effects such as theincrease in protein kinase-C activity [382]. Similarly to the phyto-
chemicals above described, also ALC has been found to up-regulate
HO-1 expression reducing the Aβ toxicity in primary cortical neuro-
nal cultures [383] and to prevent age-related changes in mitochondri-
al respiration through the induction of HO-1, Hsp70, Hsp60 and
Thioredoxin Reductase, and decreasing oxidative stress biomarkers
in senescent rats [370–372,378,383–386]. The HO-1 up-regulation
has been linked to activation of the trascriptor factor Nrf2 [378], im-
plying the possibility that the ALC mediated acetylation of DNA-
binding proteins, can induce post-translational modiﬁcations of criti-
cal target proteins involved in DNA competence and transactivating
activity [37,51,371,378].
Interestingly, ALC and LC have been shown to reduce apoptosis
through the mitochondrial pathway [388,390]. This anti-apoptotic ef-
fect has been observed in different cells, including neurons [390],
myocytes [391], teratoma cells [392], hepatocytes [393,394] and lym-
phocytes [395]. Particularly, in neurons [396], cellular death induced
by methamphetamine was reduced by high concentrations of acetyl-
carnitine. Acetylcarnitine protected also the dopaminergic system
against the intraventricular injection of 1-methyl-4-phenylpyridi-
nium (MPP+) in rats [397]. Less apoptosis was demonstrated in
mouse ﬁbroblasts treated with different concentrations of acetylcar-
nitine [389]. ALC and LC promoted neuronal survival and mitochon-
drial activity in addition to having anti-apoptotic effects in serum-
deprived primary culture neurons [390]. In another tissue culture
study, ALC treatment of TRX2-knockout DT40 cells suppressed oxida-
tive stress in mitochondria, which prevented the mitochondrial sig-
naling pathway leading to apoptosis [398]. The antiapoptotic effect
of acetylcarnitine may be related to the overexpression and activation
of HO-1, which increases the level of antiapoptotic bcl-2 protein and
inactivates the pro-apoptotic transcription factor p53 in neurons
[130]. Orally-supplemented acetylcarnitine in rats has been reported
to decrease caspase activation by increasing the level of X-linked in-
hibitor of apoptosis protein (XIAP), thus limiting the mitochondrial-
induced apoptosis in peripheral neurons [399]. Neither a protective
effect on apoptosis induction nor a decrease in XIAP level was ob-
served by these authors after carnitine administration, suggesting
that the acetyl groups of acetylcarnitine have a fundamental role in
protecting against mitochondrial-induced apoptosis.
ALC treatment has been found to produce several changes in gene
expression [400–404]. An important role in the regulation of nucler
DNA transcription was recently attributed to the acetylation and dea-
cetylation of core histone tails at lysine residues in consideration of
the activation and repression of the gene transcription induced by
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tone acetylation is the acetyl-CoA availability in the nucleo-cytosolic
pool [407]. From the analysis of the Poly(A)+RNAs isolated from
brains of rats treated with ALC the expression of two genes resulted
modiﬁed: the isoform c 14-3-3 protein, implicated in cell differentia-
tion and growth [401,408,409] was up-regulated and the precursor
mitochondrial P3 of ATP synthase lipid-binding protein, involved in
transmembrane proton conduction, [410] was down-regulated. In ad-
dition, the gene coding for Hsp72 was up-regulated by treatment
with ALC, which appears to help establish a cytoprotective state in in-
ﬂammation, neurodegenerative disorders, and aging [385,401]. In ad-
dition to acetylation of histone proteins, site-speciﬁc acetylation of
non-histone proteins plays an important role in transcriptional regu-
lation. In particular, high mobility group (HMG)-box proteins are
acetylated [411]. The mitochondrial transcription factor A (TFAM) re-
quired for mitochondrial DNA replication, contains two HMG-box-
like domains. The total amount of TFAM increases in the liver, cere-
bellum and kidney with aging [412].
Acetylation can control the activity of mitochondrial enzymes, and
possibly de novo synthesis of acetyl-CoA in mitochondria. Mitochon-
drial matrix- acetyl-Coa synthetase is reversibly acetylated at a lysine
residue in the active site of the enzyme. The deacetylation of this site
induced by the nicotinamide adenine nucleotide (NAD+)-dependent
deacetylase silent information regulators (sirtuin, SIRT3) activates the
enzyme [48,413]. It is conceivable that this modiﬁcation can alter pro-
tein conformation and consequently its function. Moreover, gluta-
mate dehydrogenase is another target for both SIRT3 [414] and
SIRT4 [415] and is inhibited upon deacetylation. As a result, cyto-
chrome b content increases, leading to increased activity of electron
transport chain (ETC.) complexes, associated with stimulation of oxi-
dative phosphorylation [416].
Oral acetylcarnitine supplementation in rats increases soleus mus-
cle mitochondrial content, nuclear transcripts of factors involved in
mitochondrial biogenesis (PGC-1α, NRF-1, TFAM), as well as the
level of mitochondrial transcripts (COX I, ATP6, ND6, 16S rRNA),
and prevents the unloading-induced downregulation of mRNA levels
of kinases able to transduce metabolic (AMPK) and neuronal stimuli
(CaMKIIβ) [400,417]. The activity and amount of HO-1 in cell culture
increased by ALC treatment in a dose- and time-dependent manner
[378]. Further, HO-1 was shown to increase mitochondrial biogenesis
in cardiomyocytes via the transcriptional control of the nuclear respi-
ratory factor-1 and 2 (NRF-1, 2) [52]. As a support of the ALC role in
stabilizing mitochondrial transcripts or mitochondrial protein syn-
thesis, recent data demonstrated that the decreased levels of a ribo-
somal RNA (12SrRNA) and a messenger RNA (mRNA for the subunit
I of complex IV) were reversed in the brain and cardiac muscle of
old rats 1 h after acetylcarnitine administration [418]. In addition,
ALC treatment was able to contrast in heart mitochondria the reduc-
tion of cardiolipin content, the alteration of cholesterol/phospholipid
ratio, the decrease of transport activity of adenylic nucleotides, pyru-
vate, phosphate and acylcarnitines [419–421]. Furthermore, the in-
crease in the content of TFAM, which controls mitochondrial DNA
transcription and translation, remains in skeletal muscle one month
after the withdrawal from chronic acetylcarnitine supplementation,
indicating the long-lasting effect of acetylcarnitine on mitochondria
[422]. However, even if interesting ﬁndings are emergeng relative to
the protective action of carnitine and ALC, particularly in relation to
leading role of different vitagenes in many of these effects, further re-
search is needed to fully clarify the ALC mechanisms in balance oxida-
tive stress according to a hormetic dose–response relationship and its
potential cytoprotective role. In this context, the interesting study
carried out by Calabrese et al. [378] demonstrated the ability of ALC
to increase the expression of OH-1 in astrocytes both in absence or
presence of an oxidative stress stimulus and this does not allow to ex-
trapolate a deﬁnite conclusion regarding the role of ALC as a defense
mechanism after an external damage of the homeostatic equilibriumor as itself a preconditionating agent. Very importantly, the ALC capa-
bility to potentiate cellular stress response through the HO-1 path-
way, appears to be a promising alternative therapeutic approach for
those pathophysiological conditions where stimulation of this re-
sponse is warranted [378].
8.5.2. Carnosine
Carnosine is a simple dipeptide, β-alanyl-L-histidine, that was iso-
lated from Liebig's meat more than a century ago [423] and was sub-
sequently classiﬁed as a histidine containing dipeptide by Krimberg
[424,425], who demonstrated the hydrolysis of carnosine to its con-
stituent amino acids (β-alanine and histidine) [426]. Carnosine is en-
dogenously formed mainly in muscle and brain tissue, by bonding
histidine and β-alanine in a reaction catalyzed by carnosine synthase
[426]. It is present in vertebrate brain, cardiac muscle, kidney, stom-
ach and high millimolar concentrations are found in the olfactory
bulbs and in skeletal muscle [427–434]. Diet inﬂuences tissue carno-
sine concentrations [435–437]. Within the organism, carnosine
breakdown is catalyzed by a speciﬁc carnosinase and a less speciﬁc
homocarnosinase which are present in many tissues, with the excep-
tion of skeletal muscle [427,438,439]. The products of carnosine hy-
drolysis are metabolized and excreted in the urine. Many
hypotheses have been made regarding the cellular action of carnosine
as anti-oxidant and oxygen free radical scavenger, physiological buff-
er, histidine source, regulator of enzyme activity, metal-ion chelator,
carbonyl scavenger, antiglycator, neurotransmitter, would healing
agent and immunostimulant [430,440–442]. Among antioxidant
mechanisms reported for carnosine, its ability to inactivate reactive
oxygen species, scavenge free radicals, such as hydroxyl, superoxide
radicals and singlet molecular oxygen, and chelate pro-oxidative
metals, like copper and iron has been reported [441,443–447]. It has
been shown to delay aging in cultured human ﬁbroblasts [448] and
to be neuroprotective because of its ability to counteract both oxida-
tive and nitrosative stress related to several pathological conditions
including ischemia [449–452], methamphetamine neurotoxicity
[453] and neurodegenerative disorders [454,455]. Regarding the
mechanisms leading to oxidative stress response, carnosine, adminis-
tered to astrocytes prior to the LPS/INFγ stimulus, prevented the up-
regulation of iNos and the induction of both HO-1 and Hsp70 [387].
These data are in line with recent ﬁndings demonstrating that HO-1
can be repressed following oxidant conditions. In contrast to the gen-
eral agree that HO-1 overexpression was a common feature during
oxidative stress, recent works demonstrated that exposure to hypox-
ia, thermal stress, and interferon-γwas able to induce a marked HO-1
repression in human cells [51,141,456–458]. The usefulness of the
HO-1 repression relies on the possibility to maintain an efﬁcient met-
abolic balance during stressful conditions, decreasing the energy costs
necessary for heme degradation, reducing the accumulation of CO
and biliverdin which can become toxic when in excess, and increasing
the intracellular content of heme necessary for the preservation of
vital functions [459]. Unfortunately, the limited number of studies
and the lack of data regarding the role of carnosine alone on the
HO-1 induction prevent to fully clarify the role of this protein in the
stress response.
A rather unusual reported antioxidant property of carnosine
was its ability to reduce concentrations of thiobarbituric acid reactive
substances (TBARS) when added to previously oxidized lipids
[441,460,461]. If carnosine could interact with aldehydic lipid oxida-
tion products, this could potentially help protect biological tissues
from oxidation, since aldehydes can form adducts with DNA, proteins,
enzymes, and lipoproteins, causing alterations in their biological ac-
tivity [441]. In this regard, the protective anti-peroxidation function
of carnosine has been demonstrated on a variety of biomolecules in-
cluding proteins [447,462–465], lipids [464,466,467], DNA [466] and
DNA bases [443]. Initial studies demonstrated that carnosine was an
efﬁcient hydrogen ion (H+) buffer over the physiological pH range
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makes an important contribution to the maintenance of intracellular
pH, which is vital for normal muscle function during intense exercise
[469,470]. At weakly alkaline pH, carnosine is easily able to suppress
lipid peroxidation [435,428]. This allows carnosine to maintain its
suppression of peroxidation. In addition, carnosine also exhibits
heavy metal ion binding properties, which inhibit some enzymatic re-
actions [427].
Carnosine has also been demonstrated to be an effective anti-
glycating agent, at least in model systems and cultured cells [432]. The
structure of carnosine closely resembles that of preferred glycation
sites in proteins, that is, a target amino group with proximal imidazole
and carboxyl groups. Carnosine itself could, sacriﬁcially, react with
many potential glycating agents thereby protecting other potential tar-
gets against glycation [442,471]. The carnosine ability to react with
toxic aldehydes (e.g. acetaldehyde, formaldehyde, malondialdehyde
and methylglyoxal), and deoxyribose has been shown to protect cul-
tured human ﬁbroblasts and lymphocytes, rat brain endothelial cells
and Chinese hamster ovary cells, by inhibiting the protein–protein
and DNA–protein cross linking induced by those substances
[442,463,471–474]. Interestingly, the dipeptide has been shown to in-
hibit formation of protein carbonyls generated by the actions of oxygen
free radicals and related species (reactive oxygen species) as well as al-
dehydes or ketones on amino acid side chains [471,475]. Moreover, it
resulted also able to react with (i.e. carnosinylate) protein carbonyls
to form protein–carbosyl–carnosine adducts, inhibiting further cross-
linking to normal proteins [476]. Finally, carnosine can suppress AGE
formation [463] and AGE-induced protein modiﬁcation [473]. Proteo-
toxic stress, characterized by an accumulation of altered proteins de-
rived from biosynthetic errors and/or deleterious post-synthetic
polypeptide modiﬁcations, is a typical feature of aging conditions
[87,477–480]. Carnosine is able to exert anti-aging actions, induces
rejuvenating effects [448,481], and protects against telomere
shortening in cultured human ﬁbroblasts [482].
The dipeptide also extended the life-span of senescence-
accelerated mice [483]. There are many possible mechanisms by
which carnosine exert these anti-aging actions [463]. Among these,
the suppression of mRNA translation initiation [484] lowers
production of error-proteins, reduces the formation of protein car-
bonyls and increases the relative availability of chaperone and proteo-
lytic activities for the recognition and elimination of altered proteins
arising from deleterious post-synthetic modiﬁcation [108]. Carnosine
has the potential to inhibit much deleterious posttranslational poly-
peptide modiﬁcation caused by oxidative [443,485–487], nitroxida-
tive [387,488] and glycoxidative agents [461,463,472–474,489–493].
Moreover, carnosine may improve cellular ability to deal with aber-
rant proteins through the nitric oxide mediated upregulation of
certain proteolytic functions [494–501,487–494]. It was demon-
strated in carnosine-treated cultured human ﬁbroblasts [463], car-
diomyoblasts [502] and in cell-free extracts of rat brain [503].
Stress/chaperone proteins participate in the recognition and pro-
teolytic elimination of altered proteins and their upregulation is as-
sociated with increased organism longevity and suppression of
some age-related diseases [25,87,504]. Carnosine-zinc complexes
(polaprezinc) stimulate expression of certain stress (heat-shock)
proteins [505–507], which could improve cellular ability to deal
with altered proteins and may again contribute to the dipeptide's
apparent anti-aging activity.
In consideration of the carnosine properties described, the thera-
peutic role of carnosine in managing secondary diabetes complica-
tions, such as cataractogenesis and atherosclerosis should be deeply
investigated [463,508]. In fact, these complications result from pro-
tein glycation and oxidation [509,510] mediated by agents and pro-
cesses against which carnosine may, theoretically, protect [473].
Some preliminary supportive evidence from animal studies has
been obtained [432,511–513]. Glycoxidation management is alsoimportant in neurodegenerative conditions [514–520]. Chen et al.
[521] suggest that carnosine could supplement glyoxalase's action,
both by its aldehyde-scavenging action and its glyoxalase-mimetic
activity. This capacity could also suppress aldehyde-mediated tau
modiﬁcation and consequent aggregation in a mouse model of Alz-
heimer's disease [522]. Carnosine treatment reduced inﬂammation
and tissue damage in a mice animal model of spinal cord injuries
[523]. Other experimental observation provided some support for
the suggestion that carnosine could be useful in ameliorating aspects
of Parkinson's, Alzheimer's diseases and also the consequences of dis-
circulatory brain ischemia [455,523–532]. It has been suggested to be
potentially useful for treating also autism [533], Down's syndrome
[534], epilepsy [535] and aggregation processes. Further reﬁnements
have led to the synthesis of new carnosine derivatives able to survive
to carnosinase hydrolytic activity and endowed with cytoprotective
effects [536–538]. Interestingly, the different molecular behavior of
carnitine and carnosine in response to similar stress stimuli, particu-
larly in relation to the activation/repression of the Keap1/Nrf2/ARE
pathway, should merit conﬁrmation and deep future investigations.
These differences, in fact, although not fully understood, may suggest
that several factors could interplay in inﬂuencing the molecular
mechanisms at the basis of the cellular defense response. Neverthless,
the discoveries that molecules, which are toxic at high doses, play
fundamental or protective roles in cellular signaling or metabolism
at low concentrations, suggest that evolution triggered organisms to
include environmental toxins for an advantageous use [51]. Thus, it
seems important to plan future researches to deeply investigate the
leading mechanisms induced by exogenous small molecules in re-
sponse to stressfull conditions. It may be a valid tool to develop inter-
ventions able to activate hormetic signaling pathways in cells as new
approaches for the prevention and treatment of a wide range of path-
ological disorders.
9. Conclusion and future directions
Due to considerable improvement in medical and environmental
factors, in the past few hundred years, average human lifespan has in-
creased substantially, bringing demographic change in most industri-
alized countries. Nevertheless, despite our achievements in average
lifespan, the maximal lifespan of humans remains unchanged as the
latter may be genetically programmed or determined by inevitable
deleterious cell changes that occur with age. These changes are typi-
cal of the senescent phenotype and eventually lead to death. Many
types of interventions, including genetic manipulations and caloric
restriction, appear to increase the maximal life span in animal
models, but it is not yet clear whether the results from these animal
experiments will contribute to lengthening the human life span.
Among the hypotheses put forward to explain the biological process-
es underlying senescence, one theory suggests that ROS formation is
principally responsible for cell damage and senescence [539,540].
The deleterious effects of ROS could slowly accumulate over years
and lead to dysfunction of a number of cell functions. The mitochon-
drion is the main organelle for the production of ROS. Although ener-
gy generation in the mitochondrion is extremely important for
survival, mitochondrial ROS production also has some negative con-
sequences for age-related intracellular changes. However, ROS is not
only a waste of oxidative phosphorylation in the respiratory chain
but is also highly regulated signal molecules involved in cellular
stress response [541]. Cells and organisms, subjected to chronic pro-
teotoxic stress associated with diseases, undergo a global decline in
cellular function with negative consequences on viability. This in-
creases the levels of damaged proteins, resulting in a decline in mul-
tiple biosynthetic and repair activities and, over time, negatively
affects health and aging of the organism. Much evidence in the liter-
ature supports the theory that molecular determinants of longevity
inﬂuence proteotoxicity, suggesting that the integrity of the
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of the cell and the healthy state of biological processes throughout
the life span of the organism. This is achieved by a complex network
of longevity assurance processes which are controlled by vitagenes, a
group of genes involved in preserving cellular homeostasis during
stressful conditions [542]. This network responds to the age related
mitochondrial dysfunction and is modulated by mitochondrially pro-
duced ROS [51,543–545]. Thus, by sensing the nutritional status of the
whole organism as well as the intracellular nutrient and energy sta-
tus, functional state of mitochondria, and mitochondrial ROS concen-
tration, the longevity network regulates life span across species by
coordinating information ﬂow along its signaling pathways. Given
the unique roles of HSF1 and Nrf2/keap1 in stress biology and pro-
teostasis, enhanced activity of these principal regulators during de-
velopment and early adulthood is important for the stability of the
proteome and the health of the cell. To this end, the crosstalk be-
tween distinct HSFs as well as between HSF1 and Nrf2/Keap1 path-
way, only recently uncovered, raises obvious questions about the
stoichiometry between the components in different complexes resid-
ing in different cellular compartments, and the mechanisms by which
the factors interact with each other. Interaction between members of
the vitagene system, HSFs and Nrf2/Keap1-related, could lead to new
therapeutic approaches for protein-folding diseases, metabolic disor-
ders and cancer, as well as healthy aging.
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